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CHAPTER I 
 
INTRODUCTION 
 
Protein kinases 
Protein kinases are molecular switches that facilitate signal transduction 
by catalyzing the transfer of the γ-phosphate of ATP to the hydroxyl group of 
serine, threonine, or tyrosine. A catalog of the protein kinase complement of the 
human genome identified 518 putative protein kinase genes, which constitute 
about 1.7% of all human genes (Manning et al., 2002). Given that they constitute 
such a large component of the eukaryotic genome, it is no surprise that kinases 
contribute substantially to the signal transduction events that dictate cell 
physiology. Through tight regulation of their catalytic activity, kinases regulate 
cellular processes such as apoptosis, differentiation, metabolism, transcription, 
cell cycle progression, cytoskeleton rearrangement and cell motility. Mutations of 
protein kinases often leads to dysregulation of signaling pathways, which is 
known to cause a wide range of human diseases and cancers.  
Since protein kinases have evolved unique mechanisms to impede 
catalytic activation, each class of kinase has a unique structure in its inactive 
state. When active, however, protein kinases share a striking similarity in their 
catalytic domain. In 1991, X-ray crystallographic studies solved the first protein 
kinase three-dimensional structure, that of cyclic AMP-dependent protein kinase 
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(also known as protein kinase A (PKA)), (Knighton et al., 1991). From this and 
other studies, it has been determined that the protein kinase domain is separated 
into two subdomains, termed lobes. The N lobe, which is the smaller N-terminal 
portion, consists of a five-stranded β sheet and one prominent α helix, while the 
larger C lobe is predominantly helical. ATP is bound in a deep cleft between the 
N and C lobes. A phosphate-binding loop, or P loop, that contains a conserved 
glycine-rich sequence motif (GXGXXG) is situated above the ATP. The glycine 
residues allow the loops to approach the phosphates of ATP close enough to 
facilitate coordination via backbone interactions. A centrally located loop known 
as the activation loop provides a platform for the peptide substrate, which binds 
across the front end of the nucleotide binding pocket, close to the γ-phosphate of 
ATP. When the kinase is active, this loop can be phosphorylated, which 
stabilizes it in an open conformation that is permissive for substrate binding. 
Completion of phosphotransfer requires precise spatial arrangement of several 
conserved catalytic residues that reside in the catalytic loops and that interact 
with the attacking hydroxyl side chain of the substrate. Proper coordination of 
ATP binding, association with substrate, and activation promote phosphotransfer, 
which often results in signal propagation in the cell (Hanks et al., 1988; Huse and 
Kuriyan, 2002).  
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Tyrosine kinases 
In 1979, Eckhart et al. discovered protein kinase-like activity in 
immunoprecipitates from polyoma T antigens that had the unusual property of 
specifically phosphorylating tyrosine (Eckhart et al., 1979). A year later, Hunter 
and Sefton made the important finding that the transforming protein of Rous 
sarcoma tumor virus, v-SRC, is also able to phosphorylate tyrosine residues 
(Hunter and Sefton, 1980). This suggested that deregulated protein tyrosine 
phosphorylation could play a role in carcinogenesis. It is now known that src is 
one of 32 non-receptor tyrosine kinases (NRTK), which are also referred to as 
cytoplasmic tyrosine kinases. In addition to the src family kinases, there are eight 
other NRTK subfamilies: Csk, Ack, Fak, Tec, Fes, Syk, Abl and Jak classes.  
NRTKs have emerged as an important contributor to initiation and progression in 
a variety of human cancers. Src, the first identified oncogene, has particularly 
been implicated in tumorogenesis; upregulated or mutated src activity has been 
reported in breast, colon, pancreas, lung, ovarian, esophageal, gastric, and skin 
cancers (reviewed in (Irby and Yeatman, 2000)). Members of the other 
cytoplasmic tyrosine kinase families are also dysregulated in human cancers. For 
instance, activation of Ack (through overexpression or mutation) leads to 
enhanced cell motility in human breast cancer cell lines (van der Horst et al., 
2005), which is crucial to metastasis and correlates with poor prognosis.  
Of the 90 known tyrosine kinases, 58 are receptor tyrosine kinases (RTK), 
which are distributed among 20 subfamilies (Manning et al., 2002). More than 
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50% of these are mutated or overexpressed in human hyperproliferative diseases 
and are thus considered viable targets for cancer therapy. Mutations in receptor 
tyrosine kinases, as well as aberrant activation of their downstream signaling 
pathways, have been linked to inflammation, diabetes, arteriosclerosis, 
angiogenesis, and bone disorders, in addition to a multitude of different types of 
cancers (Lemmon and Schlessinger, 2010). 
 
Signal transduction through receptor tyrosine kinases 
 One of the early challenges in the RTK field was determining the 
molecular mechanisms though which the receptors transduce signals across the 
plasma membrane. In the early 1980s, three reports showed that the RTKs 
epidermal growth factor receptor (Zhang et al.) (Ushiro and Cohen, 1980), the 
insulin receptor (INSR) (Kasuga et al., 1982), and the platelet derived growth 
factor (PDGF) receptor (Ek et al., 1982) are tyrosine kinases activated by their 
respective ligands. These data helped garner support for the concept of signaling 
mediated by tyrosine phosphorylation. Hunter and colleagues supplied additional 
experimental evidence for this concept by showing that stimulating NIH-3T3 cells 
with PDGF and A431 cells with EGF leads to rapid tyrosine phosphorylation of 
intracellular proteins downstream of the activated receptors (Cooper et al., 
1982),(Hunter and Cooper, 1981). In a pivotal study published in 1986, Riedel et 
al. generated a chimeric receptor that fused the extracellular region of INSR with 
the transmembrane and intracellular domains of EGFR. They made the 
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unexpected discovery that insulin binding activated the EGFR kinase domain, 
suggesting that individual RTKs use similar mechanisms for signal transduction 
across the plasma membrane (Riedel et al., 1986).   
 
Structure and activation mechanism of RTKs 
 In the last 25 years, the general structure and activation mechanism of 
receptor tyrosine kinases has been determined. All RTKs have a common 
molecular architecture, containing a ligand binding domain in the extracellular 
regions, a single transmembrane helix, a tyrosine kinase domain, and regulatory 
regions in the cytoplasmic domain (Lemmon and Schlessinger, 2010). Consistent 
with the key regulatory role of RTKs, the basic structure, mechanism, and cellular 
signaling pathways initiated by RTKs are highly conserved throughout evolution- 
from the nematode Caenorhabditis elegans to humans. In general, receptor 
tyrosine kinases are activated by ligand binding, which induces receptor 
oligimerization (Ullrich and Schlessinger, 1990). The bound ligand stabilizes the 
interaction between individual receptor molecules to form a receptor dimer. In 
some cases, the single membrane-spanning α helix also contributes to 
dimerization. Once ligand has bound to a receptor, self-association of the 
extracellular domains guides the intracellular domains into a dimeric 
conformation. Subsequently, one receptor in the dimer phosphorylates one or 
more tyrosines on its dimerization partner, which then serves as a site for 
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assembly and activation of intracellular signaling effectors (Lemmon and 
Schlessinger, 2010).  
 Although there is redundancy in the basic mechanisms leading to RTK 
activation, there are substantial differences in how each receptor binds to ligand, 
oligerimizes, transphosphorylates, and mediates downstream signaling. Early 
studies suggested a straightforward mechanism for ligand-induced dimerization 
whereby a bivalent ligand simultaneously binds two receptors and crosslinks 
them together into a dimer. This was supported by evidence from crystal 
structures of receptors such as the Eph receptor (Himanen and Nikolov, 2003), 
the nerve growth factor/ neurotrophin receptor TrkA (Wiesmann et al., 1999), the 
stem cell receptor KIT (Liu et al., 2007a) and  the Flt1 vascular endothelial growth 
factor receptor (Wiesmann et al., 1997) bound to their respective ligands. 
However, recent structural studies have provided additional insight into other 
mechanisms that mediate dimerization. On the opposite end of the spectrum 
from bivalent ligand-induced dimerization is receptor-mediated dimerization. 
Ligand binding to ErbB receptors triggers conformational changes within the 
molecule that exposes a previously occluded dimerization arm (Garrett et al., 
2002). In this type of dimerization, the ligand does not directly crosslink the dimer 
interface. Some studies suggest that EGF binds to and activates pre-existing 
EGFR oligomers, however the precise nature and size of the oligomers is not 
known (Clayton et al., 2005; Gadella and Jovin, 1995). Lastly, some RTKs utilize 
a combination of ligand-mediated and receptor-mediated dimerization. For 
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example, dimerization of the fibroblast growth factor receptor (FGFR) requires an 
FGF monomer to come into contact with two FGFRs simultaneously, and the 
resulting dimer is stabilized by heparin binding (Schlessinger et al., 2000).   
 Each RTK is uniquely autoinhibited by a specific set of intramolecular 
interactions. Upon ligand binding-induced dimerization, receptor tyrosine kinases 
release their autoinhibition to activate the intracellular tyrosine kinase domain. 
While crystal structures indicate that the activated forms of the tyrosine kinase 
domains are very similar, the inactive forms are substantially different from 
receptor to receptor and likely contribute mechanistically to receptor regulation 
(Huse and Kuriyan, 2002). Upon release from auto-inhibition, the first substrates 
that RTKs phosphorylate are tyrosines on the receptors themselves, and this 
autophosphorylation occurs in trans (Honegger et al., 1989; Till et al., 2002). The 
resulting phosphotyrosines serve as binding sites for the downstream signaling 
effecters and adaptors that are recruited to facilitate signal transduction, resulting 
in various biological outputs. 
  
Discovery of EGF and EGFR  
In 1962 Stanley Cohen isolated and characterized a salivary-gland protein 
that induced precocious tooth eruption and eyelid opening when injected into 
newborn mice (Cohen, 1962). This novel substance was termed epidermal 
growth factor, since it stimulated the proliferation of epithelial cells derived from 
chick embryos (Cohen, 1965). Subsequently, Carpenter et al. confirmed the 
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presence of specific sites that bound 125I-labeled EGF on the surface of 
fibroblasts (Carpenter et al., 1975). These binding sites were later identified as 
the EGF receptor (Zhang et al.), a 170-kDa membrane component that showed 
increased 32P incorporation in response to EGF treatment of epidermal 
carcinoma cells (Carpenter et al., 1978).  
During the 1980ʼs, cDNA cloning techniques facilitated the cloning of large 
gene transcripts. A team of scientists from Genentech, the Imperial Cancer 
Research Fund, and the Weizmann Institute of Science isolated and 
characterized the cDNA of human EGFR from A431 tumor cells and normal 
placental cells (Ullrich et al., 1984). This was the first complete amino-acid 
sequence of a cell-surface receptor with signaling ability, and it provided detailed 
insights into the molecular architecture of EGFR (Gschwind et al., 2004). 
Subsequently, a search amongst known protein sequences revealed a high level 
of similarity between the EGFR peptides and sequences of the avian oncogene 
v-erbB (Downward et al., 1984). This discovery was the first link between an 
animal oncogene and a human gene that encodes a cell growth-controlling 
protein.  
 
ErbB family members  
It is thought that humans and other jawed vertebrates have undergone two 
rounds of whole genome duplication, which duplicated every gene up to four fold 
(Dehal and Boore, 2005). While genome duplication can be a cataclysmic event 
for an organism, this double duplication enabled an enormous expansion in 
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functionality. While most duplicated genes, called ohnologs, were rapidly lost, 
13% of human genes are still recognizable as duplicates (McLysaght et al., 
2002). The ohnologs that remain are highly biased towards transcription factors 
and signaling genes (Manning and Scheeff, 2010). Currently, it is believed that 
the ErbB family originated from a single ancestral ErbB gene (Spring, 2002). All 
four ErbB ohnologs were retained after the genome quadruplication, with two 
remaining fully functional (EGFR and ErbB4), one losing its ligand-binding ability 
(ErbB2), and one lacking kinase activity (ErbB3) (Figure 1.1). The double 
duplication from a single ErbB gene gave rise to a complex array of homo- and 
hetero-dimeric receptors that mediate a diverse range of cellular signaling.  
 
ErbB ligands 
Ligand binding promotes dimerization and subsequent activation of the 
ErbB family members. EGFR, ErbB3, and ErbB4 have both overlapping and 
specific ligands; EGFRʼs cognate ligands are EGF, betacellulin (BTC), 
amphiregulin (AR), transforming growth factor-α (TGF-α), epiregulen (Peiretti et 
al.), heparin-binding EGF-like growth factor (HB-EGF), and epigen (EPG); while 
ErbB3ʼs ligands are heregulin (HRG) 1, and HRG2. ErbB4 can bind the ligands 
HRG3 and HRG4, in addition to also binding BTC, HB-EGF, EPR, HRG1, and 
HRG2 (Harris et al., 2003) (Figure 1.2).  ErbB2 has no known ligand; instead, it 
serves as the preferred dimerization partner of other ErbBs (Graus-Porta et al., 
1997). All of the ligands are generated as type 1 transmembrane proteins that  
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Figure 1.1 Schematic representation of the ErbB family with their 
respective ligands Each family member contains an extracellular region 
containing two cysteine-rich domains (green diamonds), a single transmembrane 
region (blue rectangle), and a cytoplasmic domain consisting of a tyrosine kinase 
domain (pink oval) and regulatory regions. ErbB2 has no known ligand, while 
ErbB3 has a deficient kinase domain. 
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are inserted into the plasma membrane. In response to cellular stimuli, proteases 
cleave the pro-form of the ligands to release mature growth factors.  A defining 
feature of the ErbB ligands is the presence of an EGF motif, which is a 
consensus sequence consisting of six spatially conserved cysteine residues that 
form three intramolecular disulfade bonds.  Additionally, AR and HB-EGF contain 
heparin-binding domains, while the HRGs contain an Ig-like domain (Falls, 2003; 
Harris et al., 2003) (Figure 1.2).  
 
ErbB receptor transactivation 
In addition to activation by direct ligand binding, receptor tyrosine kinases 
are transactivated by a wide variety of molecules, such as cytokines, bacterial 
products, G-protein coupled receptor (GPCR) ligands, and integrins. Previous 
reports demonstrate that transactivation occurs through two distinct mechanisms: 
the extracellular release of ligands or the intracellular activation of tyrosine 
kinases.   A recent publication by our laboratory shows that EGFR and ErbB2 
transactivation by TNF occurs in an intracellular, Src-dependant manner 
(Yamaoka et al., 2008).  In contrast, EGFR transactivation by Helicobacter pylori 
is mediated through extracellular, metalloproteinase-dependent ligand cleavage 
(Yan et al., 2009).  In 1996, Daub et al. discovered that the GPCR agonists 
endothelin-1, lysophosphatidic acid, and thrombin stimulate EGFR and ErbB2 
phosphorylation in rat fibroblasts (Daub et al., 1997). Since then, EGFR 
transactivation by GPCR ligands has been observed in a myriad of cell types,  
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Figure 1.2 ErbB ligand schematic ErbBs are activated by a family of 
EGF-like ligands, as well as by the neuregulins. EGF: epidermal growth factor; 
TGFα: transforming growth factor alpha; AR: amphiregulin; HB-EGF: heparin 
binding epidermal growth factor; BTC: betacellulin; EPR: epiregulin; EPG, epigen; 
NRG: neuregulin 
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and has been shown to be an important mediator of GPCR-induced mitogen-
activated protein kinase (MAPK) signal transduction. In the last two decades, 
EGFR has been recognized as a convergence point for diverse signal 
transduction pathways.  
 
The ADAM family of metalloproteases 
The a disintegrin and metalloprotease (ADAM) family are Zn2+-dependent 
proteases that cleave membrane-bound proteins and/ or degrade the 
extracellular matrix.  ADAMs are closely related to matrix metalloproteinases 
(MMPs), ADAM-TSs (ADAMs with thrombospondin domains), and snake venom 
metalloproteinases (SVMPs). Twenty-one ADAMs have been described in the 
human genome, but only 13 of these are proteolytically active (Edwards et al., 
2008).  ADAMs are involved in the proteolytic cleavage of a wide variety of 
membrane-bound proteins, and play a key role in growth factor receptor 
transactivation. All known ErbB ligands can be cleaved by members of the ADAM 
family. For instance, HB-EGF is cleaved by ADAMs 9, 10, 12, and 17; 
betacellulin is cleaved by ADAMs 10 and 17; epiregulin is cleaved by ADAM 17; 
and neuregulin is cleaved by ADAMs 17 and 19 (Higashiyama and Nanba, 2005; 
Montero et al., 2000; Shirakabe et al., 2001).   
ADAMs often have tissue-specific functions and promote different 
physiological processes, which range from migration and cellular adhesion, to 
proliferation and fertilization. Given their diverse signaling targets, it is not 
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surprising that ADAMs have been implicated in numerous diseases, such as 
Alzheimerʼs, rheumatoid arthritis, diabetes, and heart disease (Gooz, 2010). 
Additionally, there is substantial evidence supporting a role for ADAMs in cancer 
progression and metastasis. ADAM12 overexpression promotes breast cancer 
progression (Kveiborg et al., 2005), while ADAM12 deficiency reduces prostrate 
tumor growth and progression (Peduto et al., 2006). ADAM 9 promotes colon 
cancer cell invasion in vitro (Mazzocca et al., 2005), and ADAM-15 loss 
decreases prostate cancer metastasis to bone (Najy et al., 2008). ).  It is not 
completely understood how metalloproteases are activated, but increased 
expression of metalloproteinases has been observed in almost every disease 
where inflammation is present (Manicone and McGuire, 2008).  Interestingly, 
although metalloproteinases are often amplified in tumors, chemotherapies 
targeting metalloproteinases have not proven effective (Coussens et al., 2002).  
One plausible explanation for this is that metalloproteinases have both a 
protective function (repair after inflammation) as well as a harmful role (increased 
growth factor signaling).  
 
TNF-alpha converting enzyme  
TNF-alpha converting enzyme (TACE, or ADAM17) is a member of the 
ADAM family that is known to play a role in ligand cleavage, as well as in 
inflammation.  TACE is a ubiquitously expressed protease involved in the 
ectodomain shedding of a wide variety of transmembrane proteins, such as 
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growth factor ligands, cytokines, and receptors. As its name implies, TACE was 
discovered in 1997 as the enzyme responsible for cleaving the membrane-bound 
TNF precursor into its soluble form (Black et al., 1997; Moss et al., 1997).  
The structure of TACE is similar to that of other ADAMs: it contains a 
prodomain, a metalloenzyme or catalytic domain, a disintegrin domain, a 
cysteine-rich domain, followed by a transmembrane domain and a cytoplasmic C-
terminus (Figure 1.3). The prodomain of TACE inhibits the proteinʼs catalytic 
activity until it is removed by furin, a pro-protein convertase, in the trans Golgi 
network (Schlondorff et al., 2000). However, some studies show that removal of 
the prodomain in not necessary for TACE transport to the cell surface, since 
immature TACE is found in the plasma membrane even following furin inhibition 
(Peiretti et al., 2003).  It is thought that the metalloprotease is packaged into lipid 
rafts during transport through the Golgi network, and that this aids in TACE 
activity regulation by keeping the enzyme separated from its substrates (Tellier et 
al., 2006). TACE activation is also regulated by tissue inhibitors of 
metalloproteinases-3 (TIMP-3), which inhibits TACE by binding to a hydrophobic 
pocket in its catalytic domain.  While the interactions that inhibit TACE activation 
have been studied, much less is known about how the enzyme is actually 
activated and how it recognizes substrate. 
Diaz-Rodriguez et al. have shown that phorbol ester (PMA) and EGF 
induce TACE phosphorylation on threonine 735 in the cytoplasmic tail of the 
metalloprotease. ERK mediates this activation, which results in cleavage of the  
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Figure 1.3 TACE structural schematic TNF-alpha converting enzyme (TACE), 
also known as a disintegrin and metalloprotease 17 (ADAM17), is a 
metalloprotease that is responsible for cleaving a variety of ligands, cytokines, 
and receptors. Threonine (735) and Serine (819) have been demonstrated as 
cytoplasmic phosphorylation sites. ERK and p38 activate TACE by 
phosphorylating T735; Src also activates TACE through an unknown mechanism. 
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transmembrane TrkA neurotrophin receptor in CHO cells and HEK293 cells 
(Diaz-Rodriguez et al., 2002). Other groups have also shown that PMA and EGF 
induce serine 819 phosphorylation on TACE in HeLa cells, also in an ERK-
dependent manner (Fan et al., 2003). ERK is not the only MAP kinase capable of 
inducing TACE phosphorylation on T735; in C-α cells (derived from CHO cells) 
p38-dependent TACE activation leads to TGF-α cleavage and subsequent 
EGFR-dependent cellular proliferation (Xu and Derynck, 2010). Also, both 
constitutively active Src and endogenous Src induce TACE activation in COS7 
and MCF7 cells, leading to TGF-α cleavage (Maretzky et al., 2011). Given these 
different activation mechanisms, it is likely that TACE catalytic activity is 
regulated in a tissue-specific and stimulus-specific manner.  
Although the cleavage sites of several TACE substrates (such as TNF and 
growth hormone receptor) have been identified, there does not seem to be a 
classical TACE cleavage sequence. Instead, it is postulated that position of the 
cleavage site is more important that the actual sequence. There is some 
evidence that the “stalk region” between the transmembrane region and the first 
globular part of the substrate determines whether TACE can cleave a protein 
(Hinkle et al., 2004; Schlondorff and Blobel, 1999; Wang et al., 2002).  
 
ErbB4 
ErbB4 is the last identified member of the EGFR family of receptor 
tyrosine kinases. The 180 kD glycoprotein was discovered in 1993 by Gregory 
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Plowman. Plowman et al. designed degenerate oligonucleotide primers that 
matched a region of the mouse genome encoding conserved amino acids in the 
kinase domains of EGFR, ErbB2, and ErbB3. Following PCR to isolate genomic 
fragments of ErbBs1-3, they discovered a highly related, but distinct DNA 
fragment that they termed MER4. Subsequently, they used a similar strategy in 
the breast cancer line MDA-MB-453 to obtain a cDNA clone that corresponded to 
the human homology of MER4, which they termed HER4, or ErbB4 (Plowman et 
al., 1993). Like other members of the EGFR family, ErbB4 is characterized by 
two cysteine-rich domains in the ligand-binding extracellular region, a 
juxtamembrane domain, and a tyrosine kinase domain flanked by regulatory 
regions in the intracellular domain (Figure 1.4). ErbB4ʼs extracellular domain 
shares the most similarity with ErbB3, while its kinase domain exhibits 79% and 
77% identity with EGFR and ErbB2, respectively (Plowman et al., 1993).  
ErbB4 expression is essential for normal mammalian development; ErbB4 
null mice die at embryonic day 11 due to defects in myocardial trabeculae 
formation and nervous system development. Tidcombe et al. circumvented this 
dilemma by expressing ErbB4 under a cardiac-specific myosin promoter, which 
enabled studies of adult ErbB4 knockout mice. These mice exhibit aberrant 
cranial nerve architecture due to a defect in neural crest migration, as well as 
failure of the mammary lobuloalveoli to differentiate, which results in defective 
lactation (Tidcombe et al., 2003). In addition to neural, mammary, and cardiac 
tissue, ErbB4 is also expressed in the pancreas (Kritzik et al., 2000), esophagus,  
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Figure 1.4 ErbB4 schematic ErbB4 is characterized by two cysteine rich 
domains in the extracellular ligand binding domain, a protease-sensitive stalk 
sequence, and a tyrosine kinase domain in the intracellular region. Multiple 
tyrosine phosphorylation sites in the C-terminal end serve as docking site for 
adaptor and signaling proteins. 
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stomach, duodenum (Kataoka et al., 1998), lung (Liu et al., 2007b), and utererus 
(Lim et al., 1998).   
 
Mechanism of Activation 
ErbB4 can be activated by any of several EGF-like ligands, such as HB-
EGF, betacellulin, and epiregulin, as well as members of the heregulin/ 
neuregulin family, which includes heregulins 1-4. In the absence of ligand, ErbB4 
is made up of four discrete subdomains that adopt an autoinhibited conformation 
(Bouyain et al., 2005). Upon ligand binding, a domain rearrangement occurs that 
exposes previously obscured surfaces and allows them to mediate dimerization 
(Burgess et al., 2003). Crystallographic studies show that active ErbB4 kinase 
adopts an asymmetric dimer conformation that is almost identical to that 
observed for EGFR (Qiu et al., 2008). The C lobe of a “donor” receptor contacts 
the N lobe of an adjacent “acceptor” receptor and induces conformational 
changes that activate the acceptor kinase (Zhang et al., 2006b). This particular 
asymmetric interaction is similar to the activation interface between cyclins and 
the N lobes of cyclin-dependent kinase (Jeffrey et al., 1995). Since the ErbBs 
control such a diverse range of cellular processes, it is vital that they have 
evolved an activation state that minimizes inappropriate kinase activity caused by 
intermolecular collisions between receptors.  
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Signaling downstream of ErbB4 
Trans-phosphorylation of ErbB4ʼs C-terminal tyrosine residues provides 
docking sites for signaling molecules with phosphotyrosine binding (PTB) or src 
homology 2 (SH2)-domains. A tandem mass spectroscopy approach identified 19 
sites of tyrosine phosphorylation on ErbB4, which is more than have been 
identified for any other RTK (Kaushansky et al., 2008). Interestingly, all but one of 
the tyrosines that are located outside the kinase domain in the cytoplasmic region 
of the receptor are phosphorylated, and these sites seem to be more selective in 
their preference for binding partners than tyrosines in the other ErbBs 
(Kaushansky et al., 2008). Although it is possible that some of the sites of 
tyrosine phosphorylation are merely an artifact from the tandem mass 
spectroscopy approach used, it is encouraging to note that the authors did not 
find any evidence for phosphorylation of tyrosine residues in the extracellular 
portion of the receptor.  
Although a wide range of binding partners has been identified for EGFR, 
there have been far fewer studies concerning ErbB4ʼs signaling partners. 
Signaling targets of ErbB4 include PI 3-kinase (PI-3K), phospholipase C-γ (PLC-
γ), Mdm-2, Yes-associated proteins (YAP), nucleolin, Stat-5, and Mtg16 
(Kaushansky et al., 2008). Additionally, multiple Grb2 and Shc interaction sites 
and at least one binding site each for Nck and Crk have been identified through 
pull-down assays (Schulze et al., 2005). There are several regions in the C-
terminal regulatory domain that are conserved between EGFR, ErbB2, and 
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ErbB4. In particular, Y-1284 in ErbB4, Y-1248 in ErbB2, and Y-1197 in EGFR are 
in regions of high sequence homology between the receptors, and are binding 
sites for Shc (Schulze et al., 2005), an important adaptor protein that can lead to 
Ras activation via Grb2 interactions (Luzi et al., 2000). Due to Shcʼs role in 
promoting signaling downstream of growth factor receptors, ErbB4 
phosphorylation on Y-1284 is used as a marker for the receptorʼs activation.  
Interestingly, kinase-dead ErbB4 mutants isolated from cancerous cells maintain 
the ability to form heterodimers with ErbB2 and to activate MAPK and AKT 
pathways (Tvorogov et al., 2009).  
 
Alternative splicing generates four ErbB4 isoforms 
ErbB4 undergoes alternative splicing to generate four distinct isoforms that 
differ in their juxtamembrane and cytoplasmic domains. The two juxtamembrane 
domain variants are characterized by their susceptibility to cleavage by TACE 
and γ-secretase.  The JM-a isoforms contain a 23 amino acid stretch in their 
juxtamembrane domain that confers cleavage in response to ligand binding or 
PMA stimulation, releasing a 120 kDa ectodomain and an 80 kDa intracellular  
domain. The alternate 13 amino acid sequence in the JM-b isoforms is resistant 
to cleavage (Elenius et al., 1997). The two CYT variants differ in their cytoplasmic 
tail. A 16 amino acid sequence in the C-terminal domain of the CYT-1 isoforms 
serve as a binding site for PI-3 kinase and Nedd4, while the CYT-2 isoforms lack 
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this sequence and cannot signal through PI-3 kinase (Elenius et al., 1999) 
(Figure 1.5).   
 
Physiological functions of ErbB4 isoforms 
Although ErbB4 is expressed in a variety of epithelial tissues including the 
lining of the gastrointestinal, urinary, reproductive, and respiratory tracts, its 
function in these tissues has not been fully investigated. ErbB4 promotes 
chemotaxis in fibroblasts (Kainulainen et al., 2000), proliferation in primary breast 
cancer cells (Maatta et al., 2006), survival in neuronal cells (Erlich et al., 2001), 
and suppresses anoikis in Ewing tumor cells (Kang et al., 2007).  Paradoxically, 
ErbB4 also stimulates apoptosis in breast cancer cells and differentiation in the 
mammary gland (Long et al., 2003; Naresh et al., 2006).  These contradictory 
roles can partially be explained by the differing functions of each ErbB4 isoform.  
Although the majority of the published papers on ErbB4 do not distinguish 
between the specific isoforms, recently several groups have investigated how the 
alternative splicing variants affect cell survival and tumorigenesis.  While nuclear 
translocation of the JM-a, CYT-2 isoform promotes both survival and proliferation 
in breast cancer cells (Junttila et al., 2005), targeting of the JM-a, CYT-1 isoform 
to the mitochondria stimulates apoptosis (Naresh et al., 2006). Alternately, the 
Elenius laboratory has shown that the CYT-1 isoforms confer survival through PI 
3-kinase signaling (Elenius et al., 1999). PI3K promotes survival by activating  
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Figure 1.5 Schematic of the four ErbB4 isoforms Alternative splicing in the 
regions coding for the juxtamembrane and cytosolic domains generates four 
different isoforms of ErbB4. The JM-a isoforms are subject to a two-step 
proteolytic cleavage by TACE and γ-secretase, while the JM-b forms are resistant 
to metalloprotease-dependent cleavage. CYT-1 isoforms contain a PI3-kinase 
docking site as well as a Nedd4 binding site, which is absent in CYT-2 variants. 
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Akt, which then either activates pro-survival proteins or inactivates apoptotic 
proteins (Figure 1.6).  
The seemingly disparate findings concerning ErbB4ʼs role in biological 
processes may indicate a tissue and isoform-specific role for ErbB4 as either a 
tumor suppressor or tumor promoter.  Both ErbB4 juxtamembrane splice variants 
and both cytoplasmic splice variants are expressed in mouse colon epithelial 
tissue and cultured cells (Frey et al., 2009), but very little is known about the 
function of each isoform in the GI tract.  
 
Role of ErbB4 in cancer 
 There has been a great deal of interest in the last two decades concerning 
the role of ErbB family members in promoting oncogenic signaling. Given the 
proliferation and survival pathways downstream of ErbB activation, small 
molecule inhibitors and antibodies directed toward the receptors are attractive 
therapeutic agents. ErbB2 is overexpressed and/ or gene amplified in about 20% 
of all breast cancers; currently, the ErbB2 monoclonal antibody trastuzumab and 
the dual EGFR/ ErbB2 small molecule tyrosine kinase inhibitor lapatinib are 
approved for metastatic ErbB2-positive breast cancers (Gutierrez and Schiff, 
2011). Additionally, there are large scale, population based studies treating non-
small cell lung cancer (NSCLC) patients with the EGFR tyrosine kinase inhibitors 
erlotinin and gefitinib (Mok et al., 2009; Rosell et al., 2009). While the utility of 
targeting EGFR and ErbB2 in cancerous malignancies has been proven effective,  
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Figure 1.6 Schematic representation of the PI3K-AKT signaling pathway  
Following dimerization and activation of ErbB receptors, PI3K is translocated to 
the cell membrane and binds to phosphotyrosine consensus residues of the RTK 
through its p85 adaptor subunit. This results in activation of the p110 catalytic 
subunit, leading to production of PIP3. Through interactions with its pleckstrin 
homolgy (PH) domains, PIP3 recruits AKT. PTEN is a PIP3 phosphatase that 
negatively regulates the PI3K-AKT pathway. The interaction of PIP3 with the PH 
domain of AKT induces conformational changes in AKT, exposing the two main 
phosphorylation sites at T308 and S473, which are phosphorylated by PDK1 and 
PDK2. Activated AKT then interacts with a variety of signaling proteins to inhibit 
apoptosis. 
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it has not been definitively established if ErbB4 is an appropriate target for cancer 
treatment.   
 The role of ErbB4 as a tumor suppressor or an oncogene is currently quite 
controversial, with support for both claims evident in the literature. In support of a 
tumor-suppressing role, a constitutively active ErbB4 mutant inhibits the 
formation of drug-resistant colonies in the human prostate tumor cell lines DU-
145 and PC-3 (Williams et al., 2003). Another constitutively active ErbB4 mutant 
harboring an activating transmembrane mutation potentiated apoptosis in 
ovarian, prostate, and breast cancer cells lines (Vidal et al., 2007). Additionally, 
cytosolic, but not membrane-bound, ErbB4 expression in primary human breast 
tumors was associated with tumor apoptosis.  In the same cell type, the s80 
cleavage product was shown to act as a BH3 only protein that interacts with BAK 
to promote apoptosis (Naresh et al., 2006).  
 As evidence that ErbB4 is a tumor promoter, colonic epithelial cells 
overexpressing ErbB4 acquire the ability to form colonies in soft agar (Frey et al., 
2010). Likewise, ErbB4 mutations have been found in gastric carcinomas, 
colorectal carcinomas, non-small cell lung cancer, and breast tumors (Parsons et 
al., 2005) (Davies et al., 2005; Soung et al., 2006). Pricket et al. found that ErbB4 
is the most highly mutated protein tyrosine kinase in a melanoma screen, with 
19% of patients harboring a somatic mutation in the receptor (Prickett et al., 
2009).  A follow up to this study determined the melanoma samples exclusively 
expressed the cleavable ErbB4 isoform (JM-a, CYT-1 and JM-a, CYT-2), with no 
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detection of the non-cleavable JM-b isoforms (Rudloff and Samuels, 2010). 
These findings highlight the contribution individual isoforms make towards cancer 
progression, and underscore the importance of assessing which isoforms are 
expressed when studying the receptor.  
 
Gastrointestinal tract homeostasis 
The gastrointestinal tract consists of a single epithelial monolayer that 
extends from the mouth to the anus. Both the small intestine and the large 
intestine are comprised of a columnar epithelium that is invaginated into the 
crypts of Lieberkühn. Additionally, the epithelium of the small intestine contains 
finger-like projections termed villi. Cells from 6 to 10 different crypts migrate 
upwards in ordered columns to populate each villus (Schmidt et al., 1985). 
Intestinal stem cells reside in the base of crypts, where they produce progenitor 
cells that proliferate and migrate up the crypt axis. These cells differentiate into 
several principle types: mucus-secreting goblet cells, hormone-secreting 
enteroendocrine cells, and absorptive enterocytes (Cheng, 1974a; Cheng and 
Leblond, 1974a, b). The small intestine also contains antimicrobial Paneth cells, 
which do not migrate up the axis, but instead migrate to the base of the crypt 
(Cheng, 1974b). Once at the tip of the villlus (in the small intestine) or the top of 
the crypt (in the colon), the intestinal epithelial cells undergo apoptosis and are 
shed into the lumen. Through a process of sequential proliferation, migration, 
differentiation, and apoptosis, the intestinal epithelium is completely renewed 
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every five days (Hall et al., 1994). Disruptions in the delicate balance of these 
physiological processes can cause chronic diseases such as inflammatory bowel 
disease (IBD) (Figure 1.7). 
 
Inflammatory Bowel Disease 
 
History/ Discovery 
Inflammatory bowl diseases, which include Crohnʼs disease and ulcerative 
colitis (UC), are chronic diseases of the gastrointestinal tract that are 
characterized by cytokine-driven inflammation. Although the exact etiology of IBD 
is unknown, it is thought that a combination of genetic, environmental, and 
immunological factors play a role in the pathogenesis of these diseases. Crohnʼs 
disease was first seen in 1623 by the German surgeon Wilhelm Fabry (also 
known as Guilhelmus Fabricus Hildanus) following the autopsy of a young boy 
with a fibrous and ulcerated cecum ( reviewed in (Fielding, 1988)). In 1939, the 
disease was described by and named after Burril B. Crohn, an American 
physician (Crohn et al., 1984). Ulcerative colitis was first described in 1859 by the 
British physician Sir Samuel Wilks (Wilks, 1859). 
 
Symptoms and physiology  
Although Crohnʼs disease and ulcerative colitis share many symptoms, 
such as abdominal pain and cramping, diarrhea, loss of appetite, and bloody  
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Figure 1.7 Schematic of colonic epithelial crypt architecture under normal 
and inflamed conditions A) Under normal conditions, colonic epithelial cells 
migrate from the base of the crypt upwards toward the tip of the crypt, where they 
undergo apoptosis and are shed into the lumen. B) During inflammatory 
conditions, colonic epithelial cells undergo increased apoptosis, which results in 
barrier defects. Bacterial pathogens in the lumen are then able to migrate into the 
lamina propria, which causes recruitment of immune cells such as neutrophils 
and macrophages. 
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stools, there are many physiological and molecular differences in the diseases. 
Crohnʼs disease can affect any portion of the digestive tract from the mouth to the 
anus, while ulcerative colitis only affects the large bowel. Additionally, Crohnʼs 
disease causes discontinuous ulceration and full thickness bowel wall 
inflammation in both the small intestine and the colon, while ulcerative colitis is 
characterized by continuous inflammation in only the mucosa of the colon. 
Patients with Crohnʼs often have excess IL-12/IL-23 and IFN-γ/IL-17 production, 
and those with UC typically have increased IL-13 production (Fuss et al., 2006; 
Fuss et al., 2004). Both diseases are chronic and relapsing, but ulcerative colitis 
can be cured by surgical removal of the colon.  
 
Colitis Associated Carcinogenesis  
 One of the complications of recurrent bouts of intestinal inflammation in 
patients with IBD is an increased risk of colorectal cancer (CRC). IBD ranks as 
the third highest risk factor for CRC behind the genetic conditions familial 
polyposis coli (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). 
The risk of developing CRC rises with increased duration and extent of ulcerative 
colitis. Irrespective of disease extent, the cumulative probability of developing 
CRC is 2% after 10 years, 8% after 20 years, and 18% after 30 years of UC 
onset (Eaden et al., 2001). Drugs that reduce severity of inflammation tend to 
decrease the risk of developing CRC (Rutter et al., 2004). Typically, colitis-
associated carcinogenesis (CAC) arises in grossly diseased mucosa and in the 
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microscopic colitis proximal to gross colitis. The progression of CAC is similar in 
many ways to that of CRC. First, mutations accumulate in oncogenes or tumor 
suppressor genes, which often result in the aberrant activation of β-catenin 
signaling. Subsequently, single preneoplastic cells transition into aberrant crypt 
foci, followed by adenoma and then colorectal carcinoma. While CRC is thought 
to originate from environmental mutagens and hereditary mutations, CAC is 
initiated by chronic amplified levels of cytokines such as TNF, IL-17, 1L-23, IFN-
γ, and IL-6 and the tissue injury and repair these molecules cause. While both 
forms of colon cancer exhibit increased K-Ras signaling and decreased p53 
levels, CAC also displays dysregulated NF-κB, Stat3, and GSK3β signaling 
(Terzic et al., 2010). 
 
The role of the immune system in IBD 
Although the cause of IBD is not completely understood, it is thought that 
a dysregulated, aberrant immune response to intestinal flora plays a significant 
role in pathogenesis.  The intestinal inflammation associated with IBD is 
controlled by a dynamic interplay of the innate and adaptive immune systems. 
Following disruption of the intestinal epithelial barrier, antigen presenting cells 
(APC) underlying the intestinal epithelial monolayer are able to interact with the 
bacterial flora, which are normally compartmentalized in the lumen. Healthy 
individuals show immune tolerance to normal microbial antigens, but the mucosal 
immune system of patients with IBD severely overreacts to normal bacterial flora.  
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Subsequently, APC such as activated dendritic cells and macrophages secrete 
cytokines, which trigger and differentiate the T cells that activate the adaptive 
immune system.  These cytokines also trigger increased apoptosis in the 
intestinal epithelium, which leads to further barrier disruption, and additional 
exposure to microbial antigens (Strober et al., 2007). This cyclical mechanism of 
barrier disruption leads to the chronic bouts of inflammation that are a hallmark of 
IBD.  
 
 
The role of genetics in IBD 
There has been a sharp rise in the rates of IBD since the 1950s, although 
it is not entirely understood why. The highest prevalence of ulcerative colitis and 
Crohnʼs disease is in North America, the United Kingdom, and in northern 
Europe. In these countries, the rates of IBD are beginning to stabilize. However, 
in low-incidence areas such as Asia, southern Europe, and most developing 
countries, IBD rates continue to rise (Loftus, 2004).  
In addition to geographical location, there also seems to be a link between 
ethnicity and IBD incidence; ulcerative colitis is three to five times more prevalent 
in Jewish people, and children of North American Ashkenazi Jews with Crohnʼs 
disease typically experience an earlier onset of IBD (Heresbach et al., 1998; Niv 
et al., 2000). The largest independent risk factor for Crohnʼs disease or ulcerative 
colitis is a positive family history for IBD, which further supports the role of 
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genetics in these diseases. People with Crohnʼs disease have a first degree 
relative with the disease in 2-16% of cases, and those with ulcerative colitis have 
a first degree relative with UC in 6-16% of cases (Satsangi et al., 1996). 
Additionally, multiple studies have shown that monozygotic twins are significantly 
more likely to be concordant for IBD than dizygotic twins (Orholm et al., 2000; 
Thompson et al., 1996; Tysk et al., 1988). 
Both ulcerative colitis and Crohnʼs disease are polygenic diseases; several 
genome-wide scans have identified IBD susceptibility regions on 12 different 
chromosomes (Hampe et al., 1999; Peltekova et al., 2004; Stoll et al., 2004). One 
gene in particular that has been linked to inflammatory bowel disease is the 
caspase recruitment domain protein 15 (CARD15), which encodes NOD2. 
Between 10%-20% of Caucasians with Crohnʼs disease have a mutation in 
NOD2, typically presenting with Arg702Trp, Gly908Arg, or a frameshift deletion at 
Leu1007 (Hugot et al., 2001; Ogura et al., 2001a). NOD2 belongs to a family of 
intracellular proteins containing a nucleotide-binding oligomerization domain 
(NOD) linked at its carboxy terminus to a leucine-rich repeat (LRR) domain. The 
NOD domain activates the molecule following ligand recognition, while the LRR 
domain is a microbial component recognition unit that is structurally similar to the 
LRR recognition unit found in Toll-like receptors (TLR) (Tanabe et al., 2004). 
NOD2 recognizes a bacterial peptidoglycan product termed muramyl dipeptide, 
and is expressed in antigen presenting cells and in Paneth cells. Dysfunction of 
NOD2 in either of these cell types could be involved in the pathogenesis of IBD, 
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since both APCs and Paneth cells help regulate the intestinal immune response 
to bacteria.  In a healthy person, the resident microflora of the intestine does not 
provoke an inflammatory response.  However, it is hypothesized that when the 
bacterial recognition protein NOD2 is dysregulated, commensal bacteria can 
induce pro-inflammatory signaling through NOD2-mediated NF-κB signaling in a 
similar manner as pathogenic bacteria (Ogura et al., 2001b). 
 
 
Tumor Necrosis Factor signaling 
 
History/ Discovery 
In 1975 Carswell et al. identified a serum factor that induced hemorrhagic 
necrosis of sarcomas when passively transferred to tumor-bearing mice 
(Carswell et al., 1975). This protein, termed tumor necrosis factor (TNF), also 
killed tumor cells in vitro (Helson et al., 1975). Also referred to as cachectin 
because of its ability to induce cachexia, TNF is a proinflammatory cytokine that 
is primarily produced by macrophages and monocytes, although it can also be 
produced by T cells, fibroblasts, smooth muscle cells, granulocytes, 
keratinocytes, neurons, mast cells, and natural killer cells. TNF exists in the cell 
as a membrane-bound homotrimer of 26-kDa monomers (mTNF). Following 
cleavage by TACE, the cytokine is released from the cell as a soluble trimer of 17 
kDa monomers (sTNF). TNF can signal either in the membrane-bound or soluble 
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form, and the relative levels of each are determined by the inducing stimuli, the 
cell type involved, and the amounts of biological TACE inhibitors (such as 
members of the tissue inhibitor of metalloproteinase (TIMP) family) (Smookler et 
al., 2006). Both mTNF and sTNF can bind either one of the two TNF receptors: 
TNFR1 (p55) or TNFR2 (p75), which are both also trimers. Although both TNFRs 
bind TNF, they differ in cellular expression profiles, affinity for ligand, cytoplasmic 
tail arrangement, and signaling mechanism. For instance, TNFR1 is constitutively 
expressed on virtually all cell types, whereas TNFR2 is generally inducible and is 
typically expressed on endothelial and hematopoietic cells. Additionally, soluble 
TNF preferentially binds to TNFR1 (with a dissociation constant Kd ~20pM) over 
TNFR2 (Kd ~400 pM), due to a 30-fold faster dissociation rate from TNFR2 than 
from TNFR1 (Grell et al., 1998). While physiological levels of TNF (1 ng/mL) 
enhance wound closure through TNFR2, pathological levels of TNF (100 ng/mL) 
inhibit migration of intestinal epithelial cells though TNFR1 (Corredor et al., 
2003). Likewise, physiological concentrations of TNF stimulate proliferation in 
colonic epithelial cells through TNFR2, while signaling through TNFR1 inhibits 
proliferation in response to TNF at pathological levels (Kaiser and Polk, 1997).   
 
TNF signaling in disease 
   Signaling through TNF can often be a double-edged sword; at low 
concentrations TNF can augment host defense mechanisms against infection, 
but at high concentrations the cytokine can lead to excessive inflammation and 
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tissue injury. TNF signaling is mediated by adaptor proteins that bind to the 
cytoplasmic domain of the TNFRs upon extracellular ligand binding. TNFR1 
contains a death domain in its cytoplasmic region that binds TNFR-associated 
death domain (TRADD) and couples the receptor to either a nuclear factor 
kappa-B (NF-κB)-activating pathway or to an apoptosis-inducing pathway. NF-κB 
comprises a family of transcription factors that control a large number of 
inflammatory genes. Normally, NF-κB activation suppresses the apoptosis 
pathway. If, however, NF-κB activation is compromised, apoptotic signaling 
through caspase 8 and caspase 3 becomes the dominant TNFR1 mediated 
pathway (Van Antwerp et al., 1998) (Figure 1.8).  
 TNF plays an important role in regulating the inflammatory cascade that 
causes pathogenesis in chronic diseases such as psoriasis, rheumatoid arthritis, 
Crohnʼs disease, and asthma. Mice genetically engineered to overexpress TNF 
develop Crohnʼs-like inflammatory bowel disease, which seems to be mediated 
by mature T and B cells (Kontoyiannis et al., 1999). Additionally, TNF protein and 
mRNA are expressed in mast cells (Bischoff et al., 1999), macrophages, 
monocytes, and T cells in the intestinal mucosa of Crohnʼs disease and ulcerative 
colitis patients (Van Deventer, 1997). Patients with Crohnʼs disease and 
ulcerative colitis also have elevated concentrations of TNF in their intestinal 
mucosa (Van Deventer, 1997). 
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Figure 1.8 TNF receptors stimulate both apoptotic and survival signaling  
Through recruitment of adaptor proteins  to its death domain, TNFR1 promotes 
apoptosis via downstream p38, JNK, and caspase-8 signaling. In certain cellular 
situations, TNFR1 promotes survival though NFκB and ERK signaling. It is 
uncertain how TNFR2 stimulates apoptosis, since it lacks a death domain. 
However, it is thought that TNFR2 interacts with TRAF2 through a domain in its 
cytoplasmic tail, and subsequently activates caspase cleavage. 
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Drugs targeting TNF 
 Infliximab (brand name Remicade) and adalimumab (brand name Humira) 
are monoclonal antibodies that specifically bind TNF, while etanercept (brand 
name Enbrel) is a TNF-receptor Fc-fusion protein that binds TNF family members 
(Tracey et al., 2008). Some clinical studies have found that TNF antagonists 
increase the overall risk of infection, particularly to tuberculosis (Harris and 
Keane, 2010; Listing et al., 2005). There have also been reports that patients 
treated with anti-TNF antibodies have an increased risk of lymphomas; however, 
the data are not yet conclusive, and the risk is currently considered limited 
enough not to be a deciding factor in whether or not to treat those with high 
disease activity (Bongartz et al., 2006).   
 
Objectives 
The mammalian gastrointestinal lining plays critical roles in nutrient 
absorption and in protecting the organism from the contents of the intestinal 
lumen.  Disruption of the intestinal epithelial monolayer by alterations in 
apoptosis, proliferation, and wound healing is a hallmark of inflammatory bowel 
disease.  While the exact etiology of IBD is unknown, it is believed that 
hyperpermeability of the intestinal barrier to bacterial products couples with an 
abnormal immune response to contribute to the pathogenesis of IBD.  One of the 
mechanisms that increases hyperpermeability of the gut barrier is an increased 
level of pro-inflammatory cytokines, such as TNF and interferon-γ (Bruewer et al., 
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2003).  TNF also activates apoptotic pathways in epithelial cells, potentially 
leading to the ulcerations characteristic of IBD.   
Members of the ErbB family of receptor tyrosine kinases are vital for 
monolayer restitution and injury repair.  Our laboratory has shown that ErbB4 is 
upregulated in mouse models of colitis and is activated in response to TNF (Frey 
et al., 2009).  Coupled with our observation that ErbB4 is necessary for cell 
survival in the presence of TNF (Frey et al., 2009), this suggests that ErbB4 is a 
key mediator of intestinal epithelial layer homeostasis during inflammatory insult.  
On the other hand upregulation and increased signaling through ErbB4 during 
colitis could have severe consequences for the GI tract, since several types of 
cancer display ErbB4 amplification.  ErbB4 activation in response to inflammatory 
cytokines may contribute to the colorectal carcinogenesis that is a common 
complication of IBD.  Although the roles of EGFR, ErbB2, and ErbB3 during 
intestinal pathologies have been explored, very little is known about how ErbB4 
functions in the gastrointestinal tract. The experiments detailed in this thesis are 
designed to fill this gap in knowledge by exploring the role of ErbB4 
transactivation in maintaining intestinal epithelial monolayer integrity during 
pathologies such as colitis.   
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Chapter II 
 
MATERIALS AND METHODS 
 
Cell Culture  
Conditionally immortalized young adult mouse colon (YAMC) epithelial 
cells (Whitehead et al., 1993), Madin-Darby Canine Kidney (MDCK), and 
Immorto-Min Colon Epithelial (IMCE) cells were provided by Dr. Robert 
Whitehead (Vanderbilt University); TACE -/- lines stably expressing wildtype 
TACE and vector were obtained from Dr. Peter Dempsey (University of Michigan) 
(Garton et al., 2003). YAMC, IMCE, and TACE -/- lines were all maintained in 
RPMI 1640 medium containing 5% FBS, 5 U/mL of murine interferon (IFN)-γ 
(Intergen, Norcross, GA), 5 µg/mL insulin, 5 µg/mL transferron, 5 µg/mL selenous 
acid (Eto et al.) (BD Biosciences, San Jose, CA) and 100 U/mL penicillin and 
streptomycin and grown under permissive conditions at 33°C with 5% CO2. Prior 
to all experiments, cells were transferred to 37°C (nonpermissive) conditions and 
cultured in medium with streptomyocin, penicillin, and with either 0.5% FBS or no 
FBS for 24 hours. MDCK cells were maintained in DMEM containing penicillin/ 
streptomycin and 10% FBS at 37°C. Prior to experiments, MDCK cells were 
starved of FBS overnight.   
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Transfections and constructs  
Generation of ErbB4-expressing YAMC cells has previously been 
published (Frey et al., 2009). Briefly, inserts from pCDNA3.1-ErbB4 (JM-b/CYT-2 
isoform) expression vectors (provided by Graham Carpenter, Vanderbilt 
University) were PCR amplified then cut and ligated into linearized bicistronic 
LZRS-GFP vector, which was obtained from Albert Reynolds (Vanderbilt 
University). LZRS-GFP or LZRS-ErbB4-GFP was transiently transfected into 
Phoenix packaging cells (Steve Hanks, Vanderbilt University) and YAMC or 
TACE-/- MCE cells were subjected to 5 rounds of infection with filtered 
supernatant supplemented with 4 μg/ml polybrene. Infected populations were 
expanded and GFP-positive cells were sorted at the Vanderbilt Medical Center 
Flow Cytometry Shared Resource using a Becton-Dickinson FACSAria. All ErbB-
infected cell lines utilized in this study were infected with the JM-B, CYT-2 
isoform, which is not cleavable by TACE in the juxtamembrane domain.  
 Nontargeting control and EGFR-specific siRNA pools were purchased 
from Dharmacon (Lafayette, CO, USA) and transfected into YAMC cells (100 nM 
siRNA) with Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) following 
the manufacturer's protocol. 
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Table 2.1: ErbB ligand primer sequences 
 
Primer Sequence 5ʼ to 3ʼ 
HB-EGF F ATGAAGCTGCTGCCGTCG 
HB-EGF R TCAGTGGGAGCTAGCCAC 
Epigen F ATGGCTCTGGGGGTTCTGATAGC 
Epigen R TCACAATGGGCTCCCTCCAG 
Epiregulin F GTGATCCCATCATGCATCCC 
Epiregulin R ATTCTTTGCTCAAGGGTTGG 
Amphiregulin F CGCTGCTACCGCTGGCGCGC 
Amphiregulin R TATTCCCTGAAGTATCGTT 
Betacellulin F GGTAGCAGTGTCAGCTCCCT 
Betacellulin R GTGCAGACGCCGATGACTAA 
EGF F TACTCAGCGTCACAGCATGG 
EGF R AGCCACCCTCATAATCACAG 
TGA-alpha F CGACCGGACAGCTCGCTCTG 
TGA-alpha R TGGGTGTACTGAGCGAGCCC 
Heregulin1 F TGAATTTATGGAAGCGGAGG 
Heregulin1 R ATGTGCAGGGTTGTGATGAA 
Heregulin2 F TGTGCACTGACTGCGCCACC 
Heregulin2 R CGACCAGCAGGGCCACACAG 
Heregulin3 F AGGAGCCCCCAGTACGCAGG 
Heregulin3 R TGTCCTGGGCTGTGGTGCTTG 
Heregulin4 F TCCTGTGCAGGAAGGGCCAC 
Heregulin4 R  TTGGCTGGAGGCCAGGTGGA 
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Antibodies, Cytokines, and Growth Factors  
 Polyclonal antibodies used for Western blot include phosphoERK1/2 
(Promega) phospho-Y1068 EGFR, phospho-Y1248 ErbB2, active caspase-3, 
cleaved PARP, phospho-Y925 FAK, total FAK, phospho-T581 MSK1 (Cell 
Signaling), TACE, ErbB4 (Santa Cruz), and phospho-T735 TACE (Abcam). 
Monoclonal antibodies used include phospho-Y1284 ErbB4, phospho-Y1289 
ErbB3, phospho-S473 Akt, total Akt (Cell Signaling), and actin (Sigma). 
Neutralizing antibodies used in cell culture include ErbB4 (Millipore), HRG, HB-
EGF, and BTC (R&D Systems). Recombinant murine TNF was purchased from 
Peprotech (Rocky Hill, NJ). Recombinant HRG, BTC, and HB-EGF were 
purchased from R&D Systems (Minneapolis, MN). Recombinant EGF was a gift 
from Stanley Cohen (Vanderbilt University, Nashville, TN). TAPI-1 and GM6001 
were purchased from EMD Chemicals (Darmstadt, Germany). PMA was 
purchased from Enzo Life Sciences. AG1478, U0126, CGP77675, and 
SB202190 were purchased from Calbiochem.  
 
Cell lysates and Western blot analysis  
  Cell lysates were prepared by scraping cells in lysis buffer (10 mM Tris pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1 % SDS, 
0.2% NaDeoxycholate, and 0.1% phosphatase and protease inhibitor cocktails 
(Sigma)), incubating on ice for 10 min, clearing by centrifugation, then boiling the 
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supernatants in Laemmli sample buffer.  Cell lysates were run on SDS-PAGE 
gels (7.5-20% as needed) and transferred onto nitrocellulose membranes.   
 
Apoptosis assays  
Apoptosis was measured by cleaved PARP and active caspase-3 Western 
blot analysis following 3 hours of 100 ng/mL TNF and 1 µg/mL cycloheximide 
treatment. The ApopTag terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labeling kit (TUNEL; Millipore, Danvers, MA) 
was also used to label apoptotic cells. YAMC cells expressing either vector or 
ErbB4 were seeded in 4-well chamber slides (Lab-Tech) at 5x104 cells and 
placed under non-permissive conditions overnight prior to apoptosis assays.  
Cells were treated with TNF/cycloheximide for 5 hours. The TUNEL assay was 
then performed following manufacturerʼs instructions, and cells were visualized 
by differential interference contrast microscopy on a Leica DM-IRB microscope. 
 
Barrier Function Assay 
 Barrier function across YAMC monolayers was assessed by measuring 
transepithelial electrical resistance (TEER) using a World Precision Instrument, 
EVOM (Sarasota, Fl). YAMC cells were plated at 1x104 in 24 well plates with 
transwells and grown under permissive conditions for five days. Following a 24 h 
shift to nonpermissive conditions, TEER readings were taken at 0 h and 24 h 100 
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ng/ml TNF stimulation. An average of five readings was calculated for each 
TEER reading. 
 
Wound healing assay 
Cells were seeded onto 35-mm plates coated with 2.5 µg of human 
fibronectin (BD Bioscience, Bedford, MA). Using a rotating silicon tip attached to 
a drill press, eight circular wounds were made in each confluent plate. Cells were 
washed twice with PBS and incubated under nonpermissive conditions with 1 
ng/mL TNF, 100 ng/mL HRG, or 10 ng/mL EGF. Wounds were photographed at 0 
and 24 h after wounding, and the size of each wound was determined using 
ImageJ software (National Institutes of Health, Bethesda, MD). The percent 
wound closure after 24 h was calculated. Values shown are the average wound 
closure rates for all eight wounds ± SD. 
 
Proliferation Assay 
Cells were plated in 96-well dishes (5x103 per well) at 37°C, in RPMI 
containing ITS, penicillin, and streptomycin. Cultures were exposed to 1ng/mL 
TNF, 100 ng/m HRG, 10 ng/mL EGF or vehicle for 24 h. Cells were counted at 0 
and 24 h using an MTS-based colorimetric proliferation assay kit (Promega 
Corp.). 
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Statistics and replicates  
All data with error bars are representative of at least three independent 
experiments. Statistical analyses were performed using Prism software 
(GraphPad Inc., La Jolla, CA). Statistical significance of differences was 
assessed by ANOVA analysis with Bonferroni post-test. Error bars indicate 
standard error of means. 
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Chapter III 
 
TNF-ALPHA CONVERTING ENZYME-DEPENDENT ERBB4 
TRANSACTIVATION BY TNF PROMOTES COLONIC EPITHELIAL CELL 
SURVIVAL 
 
 
Introduction 
Damage to the intestinal epithelium elicits multiple signal transduction 
pathways necessary for the cell survival, proliferation, and migration responses 
that repair injury. Coordinating these responses is critical for maintenance of a 
healthy colonic epithelial barrier, while disruption in these pathways can lead to 
conditions such as inflammatory bowel disease (IBD). We have shown that the 
tyrosine kinase ErbB4 is upregulated in the damaged epithelium of IBD patients 
and in mice with chemically induced colitis (Frey et al., 2009).  ErbB4 is the most 
recently discovered member of the ErbB family of growth factor receptors, which 
includes epidermal growth factor receptor, ErbB2 (HER2), and ErbB3 (HER3). 
Binding of ErbB4 ligands, which include heparin-binding EGF-like growth factor 
(HB-EGF), betacellulin (BTC), epiregulin (EPI), and heregulins (HRG) 1-4, 
induces receptor homodimerization or heterodimerization with ErbB1-3.  
Dimerization triggers activation of intrinsic tyrosine kinase activity and auto-
phosphorylation of the cytoplasmic domain of the receptor, thus providing 
docking sites for a variety of adaptor proteins involved in the activation of 
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downstream cascades such as the phosphoinositide 3-kinase (PI3K)/Akt 
pathway (Kaushansky et al., 2008).   
In addition to direct ligand stimulation, ErbB receptors can be indirectly 
activated by other stimuli such as G protein-coupled receptor agonists (Prenzel et 
al., 1999), cytokines (Yamaoka et al., 2008), and bacterial products (Yan et al., 
2009). This cross communication enables the ErbB family to respond to diverse 
cellular signals and yield a myriad of biological responses, including survival, 
proliferation, and migration. Two distinct mechanisms of transactivation have 
been described: the activation of intracellular kinases and the extracellular 
release of ligands. Recently we have shown that EGFR and ErbB2 
transactivation by the pro-inflammatory cytokine TNF occurs in an intracellular, 
Src-dependent manner (Yamaoka et al., 2008).  However, other groups have 
shown that metalloprotease-driven ligand cleavage mediates EGFR 
transactivation following stimulation with GPCR-agonists (Schafer et al., 2004). 
Synthesized as membrane-anchored precursors, ErbB ligands are cleaved by 
members of the a disintegrin and metalloprotease family (Rose-John et al.), 
releasing soluble growth factors capable of paracrine and autocrine signaling 
(Sanderson et al., 2006). TNF-α converting enzyme (TACE/ADAM17) can cleave 
several members of the EGF-like ligand family, including HB-EGF, EPI (Hinkle et 
al., 2004), and HRG (Montero et al., 2000). The mechanism by which cellular 
stimuli activate TACE is not completely defined; however, data suggest a role for 
the mitogen-activated protein (MAP) kinases p38 or extracellular signal-regulated 
  50 
(ERK1/2) kinase, which have both been shown to phosphorylate TACE on 
Thr735 (Diaz-Rodriguez et al., 2002; Xu and Derynck). 
We have recently shown that ErbB4 expression is upregulated in the 
colonic epithelium of patients with inflammatory bowel disease and in mouse 
models of colitis (Frey et al., 2009).  Additionally, 24 hour TNF exposure 
stimulates ErbB4 expression and activation in cultured young adult mouse colon 
(YAMC) epithelial cells, through an undetermined mechanism. One of the 
hallmarks of IBD is disruption of the intestinal epithelial monolayer due to 
increased apoptosis (Edelblum et al., 2006). ErbB4 induction by TNF presumably 
provides a check on colonocyte apoptosis by promoting cell survival in the 
presence of inflammatory cytokines (Frey et al., 2009).  
The purpose of this study was to identify the mechanism by which TNF 
transactivates ErbB4, and to determine the role of this mechanism in anti-
apoptotic signaling. Herein, we report that HB-EGF release by TACE is 
necessary for ErbB4 activation following TNF stimulation.  Additionally, we show 
that TNF activates TACE in a MEK-dependent fashion, and that TACE activity 
and ErbB4 ligand binding are required for ErbB4-mediated cell survival in the 
presence of inflammatory cytokines, as well as activation of the pro-survival 
PI3K/Akt pathway. By providing the mechanism of the first example of ErbB4 
transactivation, this study fills a gap in the knowledge of how ErbB4 functions to 
protect the gastrointestinal epithelium from inflammation-induced injury, which 
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may lead to novel treatment strategies for protecting the intestinal epithelium 
from cytokine-induced injury in patients with IBD. 
 
Results 
 
TNF Transactivates ErbB4 in Colon Epithelial Cells   
Since ErbB4 expression is upregulated in the colonic epithelium of 
patients with IBD and in mice with DSS-induced colitis (Frey et al., 2009), we 
tested whether TNF could activate ErbB4 in young adult mouse colon (YAMC) 
epithelial cells stably over-expressing ErbB4 (termed YAMC-ErbB4 cells). TNF 
induced ErbB4 phosphorylation in a dose-dependent manner (Figure 3.1A), with 
the response peaking at 30 minutes and sustaining for at least 24 hours after 
treatment (Figure 3.1B). TNF also activated endogenous ErbB4 in an alternate 
colon epithelial cell line, Immorto-Min Colon Epithelial (IMCE) cells (Figure 3.2) 
as well as in Madin-Darby Canine Kidney (MDCK) cells (Figure 3.3), 
demonstrating that this phenomenon is not restricted to a single cell line or organ.  
 
TNF-induced ErbB4 Activation in YAMC Cells is mediated by HB-EGF   
Transactivation of ErbB receptors can occur through either ligand-
dependent (Yan et al., 2009) or ligand independent (Yamaoka et al., 2008) 
mechanisms. To determine which route mediates TNF activation of ErbB4 in 
intestinal epithelial cells, we utilized a neutralizing antibody that blocks the 
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Figure 3.1: TNF transactivates ErbB4 in colonic epithelial cells  A) YAMC 
cells expressing ErbB4 (YAMC-ErbB4 cells) were treated with TNF for 30 min at 
the indicated concentrations or with 10 ng/mL HRG for 10 min. Cell lysates were 
analyzed by Western blot with antibodies specific for phosphorylated (PY-1284) 
ErbB4, total ErbB4, or actin (loading control). B) YAMC-ErbB4 cells were treated 
with TNF (100 ng/mL) for the indicated time points or with HRG (10 ng/mL) for 10 
min, as a positive control for activation. 
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Figure 3.2 TNF transactivates ErbB4 in IMCE cells Immorto-Min Colon 
Epithelial (IMCE) cells were treated with 100 ng/mL TNF for the indicated times 
or with 10 ng/mL HRG for 10 min. Cell lysates were then analyzed by Western 
blot with antibodies specific for phosphorylated (PY-1284) ErbB4, total ErbB4, or 
actin. 
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Figure 3.3 TNF transactivates ErbB4 in MDCK cells MDCK cells were treated 
with TNF (100 ng/mL) for the indicated time points or with HRG (10 ng/mL) for 10 
min.  Cell lysates were then analyzed by Western blot with antibodies specific for 
phosphorylated (PY-1284) ErbB4, total ErbB4, or actin. 
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ligand binding domain of ErbB4. YAMC-ErbB4 cells were incubated with the 
blocking antibody for 1 h before treatment with TNF for 30 min or HRG for 10 
min.  ErbB4 activation was then assessed by Western blot analysis.  The ErbB4 
blocking antibody inhibited both TNF-induced activation of ErbB4 and direct 
ligand stimulation (Figure 3.4), indicating that transactivation by TNF requires 
binding of an extracellular factor.   
ErbB4 recognizes a subset of EGF-like ligands, such as HB-EGF and 
BTC, in addition to members of the heregulin family.  To ensure that the ErbB4 
blocking antibody did not cross-react with any of the closely related EGFR family 
members, YAMC-ErbB4 cells were treated with HRG (which binds ErbB3 and 
ErbB4), BTC (which binds EGFR and ErbB4), and EGF (which only binds EGFR) 
for 10 min. Figure 3.5 shows that ErbB4 blocking antibody inhibits ErbB4 
phosphorylation by its own ligands, but not by EGF.  Importantly, the ErbB4 
blocking antibody did not inhibit EGFR activation by BTC and EGF or ErbB3 
phosphorylation by HRG.  
To narrow down the identity of the ligand responsible for ErbB4 
transactivation by TNF, we utilized qualitative PCR to determine which ligands 
were expressed in YAMC cells. Table 3.1 shows the results of this PCR; EGF, 
HB-EGF, BTC, HRG-1, and HRG-2 were expressed in these cells. To determine 
which of the known ErbB4 ligands is responsible for ErbB4 transactivation by 
TNF, we treated YAMC-ErbB4 cells with TNF in the presence of HRG, HB-EGF, 
or BTC neutralizing antibodies. HB-EGF neutralizing antibody blocked both TNF 
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Figure 3.4 Ligand binding is required for ErbB4 transactivation by TNF   
YAMC-ErbB4 cells were incubated with either control mouse IgG or an ErbB4 
blocking antibody for 1 h before the addition of TNF (100 ng/mL) for 30 min or 
HRG (10 ng/mL) for 10 min. Treatment with mouse IgG served as the negative 
control. Cell lysates were analyzed by Western blot with antibodies specific for 
phosphorylated ErbB4 (PY-1284), total ErbB4, or actin. 
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Figure 3.5 ErbB4 blocking antibody specifically blocks ErbB4 ligand 
binding YAMC-ErbB4 cells were incubated with an ErbB4 blocking antibody for 1 
h before the addition of 10 ng/mL HRG, 1 ng/mL BTC, or 1 ng/mL EGF for 10 
min. Phosphorylated ErbB4 (PY-1284), EGFR (PY-1068), ErbB2 (PY-1248), 
ErbB3 (1289), or total actin was assessed by Western blot. 
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Table 3.1: Expression of ErbB ligands is YAMC cells Qualitative PCR with 
primers specific for each ErbB ligand was used to determine which ligands are 
expressed in YAMC cells 
 
 
 
 
 
Ligand Expressed? 
HB-EGF Yes 
Epigen No 
Epiregulin No 
Amphiregulin No 
Betacellulin Yes 
EGF Yes 
TGR-α No 
HRG-1 Yes 
HRG-2 Yes 
HRG-3 No 
HRG-4 no 
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and HB-EGF-stimulated ErbB4 phosphorylation (Figure 3.6A). In contrast, neither 
HRG neutralizing antibody (Figure 3.6B) nor BTC neutralizing antibody (Figure 
3.6C) attenuated TNF activation of ErbB4, although the antibodies were able to 
inhibit HRG and BTC-induced phosphorylation, respectively.  We therefore 
conclude that HB-EGF is required for ErbB4 transactivation by TNF.   
 
TACE-stimulated Release of HB-EGF Mediates TNF Transactivation of ErbB4   
TNF signaling through TNFRs is known to activate metalloproteinases, 
which are proteases that can cleave membrane-anchored ligands (Huovila et al., 
2005).  To investigate whether ligand cleavage is necessary for ErbB4 
transactivation, we treated YAMC-ErbB4 cells with the broad-spectrum 
metalloproteinase inhibitor GM6001 (50 µM) for 30 minutes, followed by TNF for 
30 minutes or HRG for 10 minutes.  GM6001 blocked ErbB4 activation in 
response to TNF, but not HRG (Figure 3.7A).  Since the metalloproteinase TACE 
has been specifically implicated in the cleavage of ErbB4 ligands (Hinkle et al., 
2004), we also treated YAMC-ErbB4 cells with the selective TACE inhibitor TAPI-
1 (10 µM, 30 min) before TNF or HRG exposure.  TNF-mediated ErbB4 
phosphorylation was completely reversed by TACE inhibition, while HRG-induced 
activation was not altered (Figure 3.7B), suggesting that TACE-mediated 
cleavage of an ErbB4 ligand mediates ErbB4 transactivation. 
To confirm that TACE is activated by TNF in YAMC-ErbB4 cells, cultures 
were treated with TNF for up to 30 min or with 20 ng/mL PMA for 1 minute, then  
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Figure 3.6 HB-EGF ligand binding mediates ErbB4 transactivation by TNF  
YAMC-ErbB4 cells were incubated for 1 h with A) HB-EGF neutralizing antibody 
B) HRG neutralizing antibody or C) BTC neutralizing antibody before stimulation 
with 100 ng/mL TNF for 30 min and with 50 ng/mL HB-EGF, 10 ng/mL HRG, or 
10 ng/mL BTC for 10 min. Treatment with mouse IgG served as the negative 
control. Cell lysates were analyzed by Western blot with antibodies specific for 
phosphorylated ErbB4 (PY-1284), total ErbB4, or actin. 
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Figure 3.7 Metalloproteases mediate TNF transactivation of ErbB4 in 
colonic epithelial cells  YAMC-ErbB4 cells were incubated for 30 min with A) 
50 mM of the broad spectrum metalloproteinase inhibitor GM6001 or B) 10 mM of 
the TACE selective inhibitor TAPI-1, then stimulated with TNF (100 ng/mL, 30 
min) or HRG (100 ng/mL, 10 min). Cell lysates were then analyzed by Western 
blot with antibodies specific for phosphorylated ErbB4 (PY-1284), total ErbB4, or 
actin. 
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lysed and analyzed for phosphorylation at a known TACE activation site (Diaz-
Rodriguez et al., 2002).  In response to TNF, TACE was phosphorylated at T735, 
with activation peaking between 2 and 5 minutes. PMA, a known TACE stimulus 
(Hahn et al., 2003), also induced TACE phosphorylation (Figure 3.8). To further 
verify that TACE is in fact the metalloproteinase responsible for TNF 
transactivation of ErbB4, we stably expressed ErbB4 in TACE -/- mouse colon 
epithelial (MCE) cells transfected with either wild type TACE or vector.  ErbB4 
was not phosphorylated in response to TNF in TACE -/- MCE cells expressing 
vector; however, re-expression of wild type TACE restored TNF-induced ErbB4 
activation (Figure 3.9).  We then took advantage of the observation that TNF 
cannot promote ErbB4 phosphorylation in the TACE -/- MCE line, by transferring 
conditioned media from YAMC-ErbB4 cells treated with TNF to the TACE null line 
and assessing ErbB4 phosphorylation by Western blot.  In TACE -/- MCE cells, 
ErbB4 was phosphorylated by conditioned media transferred from YAMC cells 
treated with 100 ng/mL TNF for 15 min (Figure 3.10), further supporting the 
hypothesis that ErbB4 transactivation by TNF is mediated by TACE cleavage of 
an ErbB4 ligand.   
 
ErbB4 Activation by TNF requires MEK kinase activity  
There are multiple routes by which TNF could stimulate TACE. One 
common mechanism of TNF-induced TACE activation is through intracellular 
kinases.  Specifically, ERK1/2 stimulates TACE phosphorylation at threonine 735  
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Figure 3.8 TACE is activated in YAMC cells treated with TNF YAMC-ErbB4 
cells were treated with 100 ng/mL TNF for various time points or with 20 ng/mL 
PMA for 1 min. Cell lysates were analyzed by Western blot with antibodies 
specific for phosphorylated TACE (PT-735), ErB4 (PY-1284), ErbB4, or actin. 
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Figure 3.9 TACE mediates TNF transactivation of ErbB4 in colonic 
epithelial cells TACE -/- colonic epithelial cells infected with ErbB4 and with 
either wild type TACE or vector added back were treated with 100 ng/mL TNF for 
30 min or 10 ng/mL HRG for 10 min. Cell lysates were then analyzed by Western 
blot with antibodies specific for phosphorylated ErbB4 (PY-1284), total ErbB4, 
TACE, or actin. 
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Figure 3.10 An extracellular factor mediates TNF transactivation of ErbB4 
in colonic epithelial cells  YAMC-ErbB4 cells were treated directly with 100 
ng/mL TNF for 5 or 15 min or 10 ng/mL HRG for 10 min. TACE -/- colon epithelial 
cells expressing ErbB4 were treated with conditioned media from the 
corresponding YAMC cells for 10 min (indicated CM). Cell lysates were then 
analyzed by Western blot with antibodies specific for phosphorylated ErbB4 (PY-
1284), total ErbB4, or actin. 
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in response to TNF treatment of HeLA cells (Diaz-Rodriguez et al., 2002), p38 
mediates TACE activation in lymphocytes and monocytes treated with TNF 
(Killock and Ivetic, 2010), and Src is required for gastrin-releasing peptide-
induced TACE activity in squamous cell carcinoma of the head and neck cell 
lines (Zhang et al., 2006a).  Since we demonstrated TNF-induced TACE 
phosphorylation at the ERK site T735 (Figure 3.8), we tested the possibility that 
the MEK/ERK cascade is required for TNF transactivation of ErbB4. YAMC-
ErbB4 cells were treated with the MEK inhibitor U0126 for 30 min before addition 
of TNF or HRG.  MEK inhibition completely blocked ErbB4 phosphorylation in 
response to TNF, as assessed by Western blot analysis (Figure 3.11A). To 
further test the hypothesis that ERK-induced TACE activation promotes ErbB4 
transactivation by TNF, we pretreated YAMC-ErbB4 cells with UO126 before 
TNF stimulation and assessed TACE activation. Blocking MEK activity reversed 
the ability of TNF to phosphorylate TACE on T-735, supporting the role of ERK 
being upstream of TACE in ErbB4 transactivation (Figure 3.11B).  In contrast to 
MEK inhibition, Src inhibition by CGP77675 (Figure 3.12A) or p38 inhibition by 
SB202190 (Figure 3.12B) did not affect transactivation.   
 
EGFR is required for TNF transactivation of ErbB4 
Following ligand binding, ErbB4 can either homodimerize with another 
ErbB4 receptor or heterodimerize with another member of the ErbB family. To  
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Figure 3.11 ErbB4 transactivation by TNF requires MEK A) YAMC-ErbB4 
cells were incubated with 10 mM U0126 (MEK inhibitor) for 1 h before the 
addition of TNF (100 ng/mL) for either 15 or 30 min. B) YAMC-ErbB cells were 
pretreated with UO126 before 5 min TNF treatment. Phosphorylation of ErbB4 
(PY-1284), TACE (PT-735), ERK1/2, or total ErbB4, TACE, ERK1/2, or actin was 
determined by Western blot analysis. 
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Figure 3.12 ErbB4 transactivation by TNF does not require p38 or Src 
kinases A) YAMC-ErbB4 cells were incubated with 2 mM of the Src inhibitor 
CGP77675 for 1 h before the addition of TNF for the indicated time points B) 
YAMC-ErbB4 cells were incubated with 10 mM SB20190 (p38 inhibitor) for 1 h 
before TNF treatment for 15 or 30 min. Phosphorylation of ErbB4 (PY-1284), 
MSK1 (positive control for p38 inhibition), or FAK (PY-925, positive control for Src 
inhibition) or total ErbB4, FAK, or actin was determined by Western blot analysis.   
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determine if EGFR activity was required for TNF transactivation of ErbB4, YAMC-
ErbB4 cells were incubated with the EGFR tyrosine kinase inhibitor AG1478, and 
then treated with TNF, HRG, or EGF. Inhibiting EGFR kinase activity with 
AG1478 completely blocked TNFʼs ability to transactivate ErbB4 (Figure 3.13A). 
AG1478 has been shown to also inhibit ErbB4 kinase activity in some studies, so 
another possible interpretation of these data is that ErbB4 kinase activity, and not 
EGFR kinase activity, is required for TNF-induced ErbB4 activation.  Likewise, 
transfection with EGFR-specific siRNA abrogated ErbB4 activation by TNF 
(Figure 3.13B). A limitation of these results is that the decrease in ErbB4 
activation could be attributed to off-target affects from the EGFRs siRNA. To 
control for this, we used scrambled non-targeting siRNA; however, the non-
targeting siRNA was not scrambled specifically from the EGFR siRNA 
sequences, so it is still possible that the results were influenced by non-specific 
affects from the siRNA.  As a further control against off-target affects from the 
EGFR siRNA, we blotted for ErbB4 expression. Figure 3.13B shows that while 
the EGFR siRNA significantly knocks down EGFR expression, there is no change 
in ErbB4 levels. Both AG1478 and EGFR siRNA also attenuated HRG-induced 
activation, which is an observation we have recently published (Frey et al., 2010). 
These data suggest that heterodimerization with EGFR is necessary for optimal 
ErbB4 activation by TNF in colonic epithelial cells.  
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Figure 3.13 EGFR is required for ErbB4 transactivation by TNF A) YAMC-
ErbB4 cells were treated with the EGFR tyrosine kinase inhibitor AG1478 (150 
nM) for 30 min before treatment with 100 ng/mL TNF, 10 min 100 ng/mL HRG, or 
10 min 10 ng/mL EGF. B) YAMC-ErbB4 cells were transfected with either EGFR 
or non-targeting siRNA and treated with TNF or HRG. Cell lysates were then 
analyzed by Western blot for phospho-ErbB4 (1284), phospho-EGFR (1068), or 
total ErbB4, EGFR, or actin. 
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ErbB4 Transactivation by TNF Promotes Colonic Epithelial Cell Survival   
We have previously shown that ErbB4 overexpression protects colon 
epithelial cells from inflammatory cytokine-induced apoptosis (Frey et al., 2009).  
To test the hypothesis that TACE-mediated transactivation of the receptor is 
necessary for this survival response, we compared apoptosis levels in YAMC-
ErbB4 cells and YAMC-vector cells following 3 hour treatment with 100 ng/mL 
TNF and 1 µg/mL cycloheximide (to stimulate apoptosis) with or without 30 min 
pretreatment with 10 µM TAPI-1 (to inhibit transactivation).  After 
TNF/cycloheximide exposure, YAMC cells overexpressing ErbB4 exhibited lower 
levels of the apoptotic markers cleaved PARP and active caspase-3 than cells 
expressing vector alone. TAPI-1 treatment blocked the ability of ErbB4 to protect 
against apoptosis, indicating a requirement for TACE activity (Figure 3.14A).  To 
corroborate these results, YAMC cells expressing either ErbB4 or vector were 
subjected to the same apoptosis assay after incubation with ErbB4 blocking 
antibody. Similar to TACE inhibition, the blocking antibody reversed the ability of 
ErbB4 to protect against cytokine-induced apoptosis (Figure 3.14B).  Finally, 
TUNEL staining was used as an independent method to verify apoptosis.  After 5 
hours of TNF/cycloheximide exposure, substantially fewer YAMC-ErbB4 cells 
were TUNEL positive compared with vector controls.  However, blocking TACE 
activity (by 30 min pretreatment with TAPI-1) (Figure 3.15) or ligand binding (by 1 
hr pretreatment with ErbB4 blocking antibody) (Figure 3.16) abrogated the ability 
of ErbB4 to protect from apoptosis. Next, we used treated YAMC cells expressing  
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Figure 3.14 ErbB4 transactivation by TNF protects colonic epithelial cells 
from cytokine-induced apoptosis.  YAMC cells expressing either vector 
(YAMC-vector) or ErbB4 (YAMC-ErbB4) were incubated with A, 10 mM TAPI-1 
for 30 min or B, ErbB4 blocking antibody for 1 h before treatment with 1 mg/mL 
cycloheximide and 100 ng/mL TNF for 3 h. Caspase-3 activation and PARP 
cleavage were assessed by Western blot analysis of whole cell lysates. Actin 
was used as a loading control. 
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Figure 3.15 TACE is required for the cell survival advantage mediated by 
ErbB4 during exposure to TNF Vector and ErbB4-expressing YAMC cells were 
incubated with 10 mM TAPI-1 for 30 min before treatment with 1 mg/mL 
cycloheximide and 100 ng/mL TNF for 5 h. Subsequently, cells were subjected to 
TUNEL apoptosis assay.  Labeled nuclei from at least 5 random fields per 
condition were counted in each experiment. 
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Figure 3.16 ErbB4 transactivation by TNF protects colonic epithelial cells 
from cytokine-induced apoptosis. Vector and ErbB4-expressing YAMC cells 
were incubated with an ErbB4 blocking antibody for 1 h before treatment with 1 
mg/mL cycloheximide and 100 ng/mL TNF for 5 h. Subsequently, cells were 
subjected to TUNEL apoptosis assay.  Labeled nuclei from at least 5 random 
fields per condition were counted in each experiment. 
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vector or ErbB4 with a cytokine cocktail (100 ng/mL TNF, 280 ng/mL IL-1b, 180 
units/mL interferon-g) for 3 hours in the presence or absence of TAPI-1, then 
measured apoptosis by Western blot. When treated with physiological levels of 
pro-inflammatory cytokines, ErbB4 protects YAMC cells from apoptosis. 
However, inhibiting TACE with TAPI-1 reversed ErbB4ʼs ability to promote 
survival in the presence of cytokines (Figure 3.17). Thus, ErbB4 transactivation 
via TACE protects colonic epithelial cells from cytokine-induced apoptosis.  
Members of the ErbB family can promote survival through activation of the 
PI3K/Akt signaling pathway (Danielsen and Maihle, 2002; Frey et al., 2009).  To 
determine if this is a result of TACE-mediated transactivation, YAMC-vector and 
YAMC-ErbB4 cells were incubated with TAPI-1 for 30 min before treatment with 
TNF for 15 minutes. Western blot analysis with an antibody specific for Akt 
phosphorylation (S473) showed that ErbB4 expression stimulates increased 
levels of TNF-induced Akt activation, and that inhibiting transactivation with TAPI-
1 abrogates this response (Figure 3.18A). Pretreatment of YAMC-ErbB4 cells 
with an ErbB4 blocking antibody also inhibits ErbB4ʼs ability to promote Akt 
activation following TNF stimulation (Figure 3.18B). In conjunction with our 
previous results showing that PI3K blockade reverses ErbB4-induced cell 
survival (Frey et al., 2009), these data indicate Akt signaling is involved in the 
pro-survival pathway elicited by TNF-induced ErbB4 transactivation in colon 
epithelial cells.  
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Figure 3.17 TACE is required for the cell survival advantage mediated by 
ErbB4 YAMC cells expressing vector or ErbB4 were incubated with 10 mM TAPI-
1 for 30 min before treatment with 1 mg/mL cycloheximide and 100 ng/mL TNF or 
with a cytokine cocktail (100 ng/mL TNF, 280 ng/mL IL-1b, 180 units/mL 
interferon-g) for 3 hours. Densitometry from Western blots of cleaved PARP and 
active caspase 3 from three experiments was quantified 
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Figure 3.18 ErbB4 transactivation by TNF promotes AKT activation A) 
YAMC-vector and YAMC-ErbB4 cells were incubated with 10 mM TAPI-1 for 30 
min or B) with ErbB4 blocking antibody for 1 hour before treatment with 100 
ng/mL TNF for 15 min. Cell lysates were then analyzed by Western blot with 
antibodies against phosphorylated Akt (PS-473), total Akt, ErbB4, or actin. 
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The role of ErbB4 in maintaining barrier function in the colonic epithelium 
 Increased apoptosis due to TNF in the gastrointestinal epithelial 
monolayer can cause breeches in the normally tight barrier (Schulzke et al., 
2006).  This causes dual problems in patients with IBD: a loss of ions and water 
into the lumen causes diarrhea, while bacterial antigens crossing the epithelium 
perpetuate the inflammatory response. Since ErbB4 overexpression protects 
from cytokine-induced apoptosis, we hypothesized that ErbB4 could also protect 
from TNF-induced barrier disruption. To test this, YAMC cells were grown to 
confluence in transwells, and transepithelial electrical resistance (TEER) was 
measured before and after 24 h TNF treatment. Figure 3.19 shows that in this 
assay TNF stimulation increases TEER, instead of decreasing it as expected. 
This likely indicates that in this particular system, the YAMC cells are not forming 
tight junctions, and thus are not generating a barrier. As such, we could not 
determine whether ErbB4 protects from TNF-induced barrier disruption in this 
system. To further test whether ErbB4 plays a role in maintaining the integrity of 
the colonic epithelial monolayer, cells that form tight junctions (such as Caco-2 
cells) could be infected with ErbB4 and TEER examined.  
 
ErbB4 overexpression does not promote proliferation or migration in colon 
epithelial cells 
 Following inflammation-induced apoptosis, restitution of the colonic 
epithelium can occur through increases in proliferation and/or migration of  
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Figure 3.19 The role of ErbB4 isoforms in barrier function: YAMC cells 
expressing vector, the JM-a, CYT-2 isoform, or the JM-b, CYT-2 isoform were 
allowed to grow to confluence, and then TEER readings were taken both before 
and after 24 h 100 ng/mL TNF treatments 
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intestinal epithelial cells. We have previously shown that low doses of TNF 
stimulate YAMC cell proliferation and migration (Kaiser and Polk, 1997). 
Additionally, ErbB4 has been shown to promote proliferation in cardiomyocytes 
(Bersell et al., 2009), neuroblasts (Ghashghaei et al., 2006), and cervical cells 
(Eto et al., 2010). ErbB4 has also been shown to promote migration of neural 
progenitor cells (Gambarotta et al., 2004). 
 To determine if ErbB4 signaling is involved in TNF-induced proliferation, 
YAMC cells expressing vector, JM-a, CYT-2 isoform, or JM-b, C YT-2 isoform 
were treated with TNF, HRG, or EGF for 24 h and subjected to the MTS 
proliferation assay (Figure 3.20). As expected, EGF promoted proliferation in all 
cell lines, as did TNF (to a lesser degree). However, there was no real difference 
in the levels of TNF-induced proliferation in the lines expressing the ErbB4 
isoforms. Similarly, the ErbB4 ligand HRG also did not promote increased 
proliferation, supporting the finding that ErbB4 signaling is not involved in TNF-
induced increases in proliferation in YAMC cells.  
 To determine whether TNF-induced migration occurs through ErbB4 
signaling, YAMC cells expressing vector, JM-a, CYT-2, or JM-b, CYT-2 isoforms 
were grown to confluence and wounded with a circular rotating silicon tip. 
Following wounding, cells were incubated for 24 h with TNF, HRG, or EGF. 
Figure 3.21 shows that while EGF promotes wound healing in all three cell lines, 
TNF only marginally increased migration. There did not appear to be a difference 
in migration between either ErbB4 isoform or vector. Additionally, HRG treatment 
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Figure 3.20 ErbB4 overexpression does not affect wound healing Circular 
wounds were created in monolayers of YAMC cells expressing vector, JM-a, 
CYT-1, or JM-b, CYT-2 isoforms of ErbB4. Cells were treated with 100 ng/mL 
TNF, 100 ng/mL HRG, or 10 ng/mL EGF for 24 h, then percent wound closure 
was measured. 
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Figure 3.21 ErbB4 overexpression does not affect proliferation YAMC cells 
expressing vector, JM-a, CYT-1, or JM-b, CYT-2 isoforms of ErbB4 were treated 
with 100 ng/mL TNF, 100 ng/mL HRG, or 10 ng/mL EGF for 24 h. Proliferation 
was measured by MTS assay, with the absorbance readings from 0h subtracted 
from absorbance at 24h.  
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did not stimulate wound healing. It is possible that any ErbB4-induced migratory 
responses were hidden by the weak TNF response, since previous data from the 
lab showed a more robust TNF-induced migration.  
 
 
Discussion 
This study describes a novel signaling cascade that promotes epithelial 
cell survival following TNF exposure. We determined the pathway through which 
TNF induces ErbB4 activation, providing the first mechanism of ErbB4 
transactivation by an inflammatory cytokine.  The data show that TNF stimulates 
ErbB4 phosphorylation through TACE-dependent HB-EGF cleavage.  
Additionally, MEK, but not p38 or Src, kinase activity was required for TNF-
induced ErbB4 activation. Furthermore, TACE-dependent ErbB4 transactivation 
is necessary for resistance from cytokine-induced apoptosis through increased 
Akt signaling. These results suggest that in the inflamed colon, TNF-induced 
ErbB4 activation may protect the epithelial monolayer from the high levels of 
epithelial apoptosis and ulcerations that are a hallmark of IBD (Hagiwara et al., 
2002; Iwamoto et al., 1996).  
Interestingly, although EGFR and ErbB4 are highly related members of the 
same receptor tyrosine kinase family, in colon epithelial cells ErbB4 
transactivation by TNF occurs through a different mechanism than EGFR 
transactivation by TNF. TNF activates EGFR through an intracellular, Src-
  84 
dependent mechanism (Yamaoka et al., 2008), whereas TNF activates ErbB4 
through extracellular, TACE-mediated ligand release. Given the wealth of data 
implicating EGFR in the pathogenesis of colon cancer (Ponz-Sarvise et al., 2007) 
and the emerging role of ErbB4 in protecting colon cells from apoptosis, 
delineating the differences in activation and signaling pathways between these 
two receptors is important for potential therapies. Understanding the mechanisms 
by which inflammatory cytokines cross-talk with ErbB family members may also 
provide more targets for treatment of colitis or for interfering with the pro-survival 
signaling that lead to carcinogenesis. 
In IBD, high levels of inflammatory cytokines, such as TNF and interferon-
γ, contribute to colon epithelial cell apoptosis, resulting in loss of mucosal 
integrity and barrier dysfunction (Edelblum et al., 2006). ErbB4 is likely important 
for protecting colon epithelial cells and limiting tissue damage during active 
inflammation. However, there is also a growing literature that suggests ErbB4 
may be involved in colorectal cancer signaling.  Inactivating somatic mutation of 
the ErbB4 kinase domain occurs in colorectal cancers (Soung et al., 2006), 
increased ErbB4 coexpression with ErbB2 has been found in late stage 
carcinomas (Lee et al., 2002), and high ErbB4 expression is seen in colorectal 
tumors (Leung et al., 2008).  We have recently demonstrated that ErbB4-
overexpressing colon epithelial cells acquire the ability to form colonies in soft 
agar in a COX-2 dependent manner (Frey et al., 2010). Furthermore, ErbB4 
deletion in human colon cancer lines increases apoptosis (Lee et al., 2009).  
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It is interesting that we observed ErbB4 transactivation leading to 
increased Akt phosphorylation; aberrant PI3K/AKT activity is implicated in 
apoptosis resistance in a variety of cancers (Hennessy et al., 2005). An 
endocrine resistant human breast carcinoma cell line that displays both ErbB4 
upregulation and increased levels of ErbB ligands (including HB-EGF, the ligand 
which activates ErbB4 in the current study) shows constitutive activation of the 
PI3K/Akt pathway (Ghayad et al., 2009). HB-EGF is expressed in a variety of 
cancers, including gastric and colon cancer (Wu et al., 2009). In breast cancer 
cells, inhibiting HB-EGF with a mutant form of the diptheria toxin, CRM197, 
attenuated Akt phosphorylation and led to significant apoptotic cell death 
(Yotsumoto et al. 2010).  Our demonstration that HB-EGF-mediated ErbB4 
transactivation by TNF leads to increased Akt activation may suggest a 
mechanism for chronic inflammation-induced carcinogenesis. While ErbB4 
transactivation by TNF may provide the short-term benefit of protecting the colon 
epithelium from apoptosis-induced ulceration during inflammatory conditions, the 
long-term consequences could potentially lead to colitis-associated 
carcinogenesis. 
Although TACE levels and activity are upregulated in patients with IBD 
and TACE-mediated TNF cleavage could potentially lead to the increased levels 
of soluble TNF seen in inflammatory diseases (Brynskov et al., 2002), it has not 
yet been resolved whether inhibiting TACE would be a viable therapy for IBD. For 
instance, in mice with TNBS-induced colitis, TACE activity was elevated, 
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resulting in concomitant increases in soluble TNF. Treatment with a 
pharmacological TACE inhibitor ameliorated TNBS-induced colonic damage and 
inflammation (Colon et al., 2001). On the other hand, when TACE expression and 
activity is reduced to <5% normal levels via genetic strategies, mice are far more 
susceptible to DSS-induced colitis (Chalaris et al., 2010; Terzic et al., 2010), 
supporting a role for TACE in protecting the GI tract from acute injury-induced 
inflammation. Likewise, when HT29 colon cells are grown to confluence, 
inhibiting TACE pharmacologically (with TAPI-2) or physiologically (with 
recombinant TIMP3) sensitizes the intestinal epithelial monolayer to TNF-induced 
barrier disruption, as measured by FITC-dextran flux (Freour et al., 2009). Our 
studies underscore the potentially complex outcomes of TACE blockade; while 
the metalloproteinase may enhance TNF release it is also required for the 
survival advantage conferred by TNF-induced ErbB4 activation.  When TACE is 
inhibited, TNF is no longer able to activate ErbB4 in colonic epithelial cells and 
instead, the pro-apoptotic effects of TNF are increased. 
While it is generally accepted that TACE plays a pivotal role in a range of 
inflammatory diseases such as IBD, rheumatoid arthritis (Newton et al., 2001), 
and heart disease (Wang et al., 2009), it is not fully understood how TACE 
activity is induced and regulated. Given the variety of stimuli that activate TACE 
and the wide range of substrates that TACE cleaves, there must be tight control 
over enzymatic activity. There have been multiple reports that phosphorylation at 
threonine 735 in the cytoplasmic tail of TACE by either p38 or ERK is important 
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for trafficking and regulation of the metalloproteinase (Diaz-Rodriguez et al., 
2002; Soond et al., 2005; Xu and Derynck, 2010). In our study, we show that 
TACE is phosphorylated at T735 following TNF stimulation, and that inhibiting 
MEK attenuates both TNF-induced TACE phosphorylation as well as ErbB4 
transactivation by TNF. These data indicate that TACE is activated by ERK at 
T735 following TNF stimulation in colonic epithelial cells, and that this activation 
is essential for ErbB4 transactivation by TNF.  It is important to note that p38 
activity is not required for transactivation, since in some cell lines p38 is 
responsible for TACE activation (Xu and Derynck, 2010). 
In summary, our data demonstrate that ErbB4 transactivation by the 
proinflammatory cytokine TNF protects colon epithelial cells from apoptosis 
through a TACE–dependent mechanism leading to downstream Akt signaling. 
This study links two known mediators of inflammatory signaling, TNF and TACE, 
to activation of the ErbB4 growth factor receptor. We have determined the 
mechanism by which TNF transactivates ErbB4. First, TNF stimulates ERK 
phosphorylation. Activated ERK then phosphorylates TACE at Threonine 735. 
Once TACE is activated, it cleaves and releases membrane-bound HB-EGF. 
Soluble HB-EGF can then bind ErbB4, inducing its phosphorylation, which leads 
to Akt activation and subsequent downstream survival signaling (Figure 1.6). 
Since TNF upregulates and activates ErbB4, and ErbB4 has recently been 
implicated in colorectal carcinogenesis, delineating the steps of this mechanism 
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could provide additional therapeutic targets for treatment of IBD and prevention 
of colitis-associated carcinogenesis.  
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Chapter IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary of Findings 
 The epithelium of the mammalian gastrointestinal lining must maintain a 
functional barrier to protect the organism from the contents of the lumen. 
Following injury to the gastrointestinal monolayer, a rapid epithelial migratory 
response coupled with tightly-regulated proliferation preserves the integrity of the 
barrier. If, however, bacteria manage to translocate across the epithelium, then 
the intestinal immune system responds by releasing antimicrobial compounds, 
initiating phagocytosis by macrophages and dendritic cells, and by producing 
inflammatory cytokines (reviewed in (Winter et al. 2010).  One of the challenges 
of the intestinal immune system is to avoid an excessive immune response 
against the normal lumenal microbiota, while maintaining the ability to trigger an 
appropriate inflammatory response against pathogenic bacteria. In particular, 
excessive inflammation through cytokine production can lead to increased 
epithelial cell apoptosis, and which leads to breaks in the monolayer and barrier 
disruption.  
 We have shown that TACE-dependent ErbB4 transactivation by TNF is 
important for cell survival in the presence of inflammatory cytokines in 
conditionally immortalized colon epithelial cells. Additionally, we have defined the 
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mechanism by which TNF transactivates ErbB4 in vitro; TNF signaling activates 
the MAP kinase ERK, which stimulates TACE proteolytic activity. Membrane 
anchored HB-EGF is then released, and is able to bind ErbB4. Following ligand 
binding, ErbB4 phosphorylation stimulates downstream Akt activation. Through 
Akt-mediated signaling pathways, TNF transactivation of ErbB4 then protects the 
colon epithelial cells from apoptosis (Figure 4.1). This is the first example of 
transactivation of the ErbB4 receptor tyrosine kinase, and shows an important 
mechanism for how the colonic epithelium maintains an intact barrier following 
cytokine disruption.  
While cytokine signaling is an important defense against pathogenic 
bacteria that manage to cross the epithelial barrier through breaks in the 
monolayer or by invading epithelial cells, excessive TNF production can cause 
damaging levels of apoptosis. This can be particularly dangerous when there are 
already breaks in the epithelial monolayer, as increased apoptosis can result in 
the ulcerations of the digestive tract that are a main symptom of IBD. By 
protecting the colonic epithelium from TNF-induced apoptosis, ErbB4 
transactivation provides a check on inflammation and promotes homeostasis of 
the gastrointestinal lining. As further support for this hypothesis, we have shown 
that ErbB4 is upregulated and activated in the colonic epithelium of patientʼs with 
Crohnʼs disease (Frey et al., 2009). It is possible that short-term treatment with 
an ErbB4 ligand could prove therapeutic to IBD patients with uncontrolled  
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Figure 4.1 Model of ErbB4 transactivation by TNF in colonic epithelial cells 
TNF stimulation of colonic epithelial cells leads to activation of ERK1/2, which 
stimulates TACE activity.  TACE cleaves membrane-bound HB-EGF, which then 
binds to ErbB4 and stimulates phosphorylation and activation.  ErbB4 
transactivation by TNF then mediates colonic epithelial cell survival through 
increased Akt signaling 
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inflammation-induced ulcerations. However, long-term activation of ErbB4 might 
be a contributor to colitis-associated carcinogenesis, since the growth factor 
receptor can stimulate survival signaling through pathways known to play a role 
in cancer. Further studies into the delicate balance between ErbB4-mediated 
protection against inflammation and activation of oncogenic signaling pathways 
will be necessary to determine the exact role the receptor plays in both IBD and 
CAC.  
 
Future Directions 
Future directions for this project will include confirming our results in vivo, 
further exploring the role that ErbB4 plays in colitis-associating carcinogenesis, 
and examining the role that ErbB4 plays during different inflammatory conditions 
in the GI tract.  
 
 
Confirming findings in vivo 
We have previously shown that mice injected with TNF for 24 h show 
increased ErbB4 expression (Frey et al., 2009).  Additionally, we see that ErbB4 
is upregulated and phosphorylated in response to TNF in vitro. An interesting 
experiment will be to determine if ErbB4 is activated in vivo in direct response to 
TNF, since it is possible that the conditionally immortalized YAMC cells have 
developed a different mechanism to respond to TNF stimulation than colonic 
epithelial cells in vivo. Wild type mice would be injected either with TNF or PBS, 
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and colon sections would be analyzed by immunohistochemistry for ErbB4 
phosphorylation. In order to confirm the mechanism for ErbB4 transactivation by 
TNF in vivo, mice would be injected intraperitoneally with a pharmacological 
TACE inhibitor before TNF treatment, and then ErbB4 phosphorylation of colon 
sections would be analyzed. Another experiment that would confirm these results 
would be to use TACE knockout mice, and to compare the ability of TNF to 
activate ErbB4 in mice lacking the metalloprotease to wild type mice. We expect 
that mice treated with TACE inhibitors and mice that do not express TACE would 
no longer show increased ErbB4 activation following TNF treatment.  
Determining the role of TACE in ErbB4 transactivation in vivo could have 
significant implications for IBD treatments. It has been suggested that TACE 
inhibition could be a valuable treatment for inflammatory diseases, since the 
metalloprotease is responsible for TNF shedding. However, mice that express 
less than 5% normal levels of TACE in the GI tract are more susceptible to DSS-
induced colitis (Chalaris et al., 2010). Potentially, TACE might also be important 
for protecting the colonic epithelium from inflammatory insult by promoting 
transactivation of ErbB4.  
On the other hand, it is possible that TACE-induced release of membrane-
bound TNF and subsequent increases in TNF signaling might override the 
beneficial advantages of ErbB4 transactivation. To test this hypothesis, we could 
treat TIMP-3 knockout mice with either TNF injections or chemically induced 
colitis and then assess inflammation and injury scores of histological colon 
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sections. Since TIMP-3 is an endogenous inhibitor of TACE, genetic ablation of 
TIMP-3 should lead to increased TACE activity- effectively generating an 
activated TACE in vivo. If TACE activity is in fact deleterious and causes 
increased inflammation, we would see increased inflammatory levels in the 
TIMP-3 knockout mice compared to wildtype mice. As evidence to support this 
hypothesis, TIMP-3 knockout mice have elevated levels of TNF and severe 
inflammation in the liver (Black, 2004). One limitation of this approach is that 
TIMP-3 can also inhibit matrix metalloproteinases, so it might be hard to interpret 
whether TACE activity or MMP activity is responsible for the results. Gaining 
insight into how TACE both protects and damages the gastrointestinal lining 
during inflammation will aid development of treatments for IBD.  
 
Determine the role of ErbB4 isoforms in promoting survival 
There are conflicting reports about ErbB4ʼs contribution to oncogenic 
signaling. Some of the confusion surrounding ErbB4ʼs role in carcinogenesis may 
be alleviated by further determining which isoforms are expressed and activated 
in the colon, both basally and in response to stimuli. While we have seen by PCR 
that both juxtamembrane variants and both cytoplasmic variants are expressed in 
the colonic epithelium of mice, we do not know the exact composition of the 
isoforms that are expressed in the GI tract. (For instance, we cannot tell at this 
point if JM-a, CYT-1 and JM-b, CYt-2 isoforms are expressed, if JM-a, Cyt-2 and 
JM-b, CYT-1 are expressed, or if all four isoforms are expressed. The sequences 
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that encode for the juxtamembrane and cytoplasmic variants are too far apart to 
design primers that amplify a stretch of the gene that encompasses both 
regions.) We are further limited in that there are no isoform specific antibodies 
available at present. Currently, there are no colonic ErbB4 knockout cells, so 
while we are able to overexpress ErbB4 isoforms in YAMC cells, the 
endogenously expressed isoforms may still be contributing to survival signaling. 
 Colon epithelial cells derived from an ErbB4 knockout mouse could be 
stably infected with each individual isoform of ErbB4, and then survival assays 
could be performed with each line. ErbB4 deletion is lethal at embryonic day 11 
due to defects in myocardial trabeculae formation. To circumvent this problem, 
Tidcombe et al. generated an ErbB4 knockout mouse that expresses ErbB4 
under a cardiac-specific myosin promoter (Tidcombe et al., 2003). This mouse 
could be crossed to the Immorto-mouse to generate conditionally immortalized 
ErbB4 knockout colon epithelial cells. Another approach to generate ErbB4 
knockout cells would be to cross mice harboring a loxP-flanked ErbB4 exon with 
mice expressing Cre recombinase driven by a villin promoter, which would cause 
intestinal-specific knockout of ErbB4.  Then, using the LZRS retroviral infection 
system, these ErbB4-/- cells will be infected with JM-a, CYT-1; JM-a, CYT-2; JM-
b, CYT-1; and JM-b, CYT-2. Subsequently, each individual line would be 
subjected to TNF/ CHX treatment, and apoptosis levels would be examined by 
TUNEL staining and by Westerns for cleaved PARP and active caspase-3. Given 
that the CYT-1 isoforms contain a PI3K binding site, we hypothesize that the 
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CYT-1 isoforms will be anti-apoptotic, since PI3K initiates several AKT pro-
survival pathways (Figure 1.6). However, Naresh et al. have shown that the JM-
a, CYT-1 s80 intracellular fragment contains a BH-3 domain that signals though 
BAK to promote apoptosis (Naresh et al., 2006). It seems ErbB4 must undergo 
proteolytic cleavage in order to stimulate apoptosis, since a JM-a, CYT-1 ErbB4 
mutant that cannot be processed by γ-secretase fails to accumulate in the 
mitochondria, and the pro-apoptotic activity of ErbB4 was abolished in cells 
expressing the mutant. Examining the role of each isoform in a completely ErbB4 
null background could shed light onto the paradoxical roles of the receptor.  
We hypothesize that in cells devoid of other isoforms, the JM-a, CYT-1 
isoform will actually promote apoptosis, while the JM-b isoforms would likely still 
promote survival signaling (since they cannot be cleaved). It is likely that the non-
cleavable isoforms (JM-b, CYT-1 and JM-b, CYT-2) are able to promote PI3K/Akt 
activation and subsequent anti-apoptotic signaling through heterodimerization 
with ErbB3, which contains several PI3K binding sites. Once processed, the 
cleavable isoforms (JM-a, CYT-1 and JM-a, CYT-2) are no longer anchored at 
the membrane and thus cannot dimerize with ErbB3. Likewise, once the JM-a 
isoforms are cleaved, they are able to enter the nucleus and interact with a 
subset of proteins that they JM-b isoforms are sequestered from. Some of these 
proteins could facilitate the pro-apoptotic signaling of the JM-a isoforms.   
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Determine the role of ErbB4 in CAC 
An important future direction for this project will be to determine ErbB4ʼs 
contribution to cell survival during inflammatory conditions in vivo. One approach 
would be to chemically induced colitis with dextran sulfate sodium (DSS) or 
trinitrobenzene sulfonic acid (TNBS) treatment in cardiac-rescued ErbB4 null 
mice, or in mice with an intestinal specific ErbB4 deletion (mediated through 
loxP/villin-Cre). Once these mice have been treated with DSS or TNBS and 
sacrificed, colon sections stained for H&E could be scored for inflammation. 
Based on our data that ErbB4 expression protects colon epithelial cells from 
TNF-induced apoptosis, we would hypothesize that histological sections from 
ErbB4 knockout mice with chemically-induced colitis would exhibit increased 
inflammation, marked by neutrophil infiltration, ulcerations of the epithelium, and 
crypt distortion and hyperplasia. 
It will also be interesting to further determine the role that ErbB4 plays in 
colitis-associated carcinogenesis. Cardiac-rescued ErbB4 null mice could be 
treated with azoxymethane (AOM, a potent carcinogen) followed by 4-7 days of 
DSS exposure. The mice would then be sacrificed and intestinal tumor 
number/severity would be scored from histological sections. Given that ErbB4 
promotes survival in inflammatory conditions, we would expect that ErbB4 
knockout mice treated with AOM/DSS would have fewer tumors/ less severe 
carcinogenesis than similarly treated wild-type mice. This would also fit with the 
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observation that ErbB4-overexpressing cells acquire that ability to form colonies 
in soft agar, which is indicative of cellular transformation (Frey et al., 2010).  
 
Identify the role of ErbB4 in H. pylori-mediated apoptosis 
It will also be interesting to determine the role of ErbB4 during other types 
of inflammation in the gastrointestinal tract. In addition to cytokine-induced 
inflammation that results from barrier defects, the GI tract is also exposed to the 
bacteria Helicobacter pylori, which can cause constant gastritis, tissue damage, 
and even carcinogenesis. We have recently seen that gastric epithelial cells co-
cultured with Helicobacter pylori show a marked increase in expression of the 
s80 intracellular fragment. It will be interesting to determine if this fragment 
originates from JM-a, CYT-1 or JM-a, CYT-2 isoforms, since in some tissues the 
isoforms differ in their ability to promote either survival or apoptosis. We have 
developed CYT-specific antibodies, which we will utilize to determine the ErbB4 
isoform that is upregulated following H. pylori incubation in gastric cells. Since 
JM-a isoforms are cleaved by γ-secretase and TACE, we will treat H. pylori 
infected gastric epithelial cells with inhibitors to these proteins and compare 
apoptosis levels between the cell lines. If JM-a, CYT-1 is the isoform 
upregulated, we hypothesize that inhibiting ErbB4 cleavage will lead to 
decreased levels of H. pylori-induced apoptosis, since the intracellular fragment 
of this isoform interacts with BAK to facilitate apoptosis. However, since the JM-
a, CYT-2 isoform lacks a Nedd4 ubiquitination site (Figure 1.5) and thus more 
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efficiently translocates to the nucleus and interacts with STAT family members 
(Zeng et al., 2009), it might promote survival signaling following H. pylori 
infection. Since H. pylori is the leading cause of gastric cancer and ErbB4 
mutations have been identified in gastric carcinomas (Soung et al., 2006), it will 
be important to determine the role that ErbB4 plays in H. pylori-mediated 
signaling.  
 
Concluding Remarks 
 ErbB4 is unique among the ErbB family members in that it is alternatively 
spliced into four isoforms with different signaling capabilities. Currently there is 
not a consensus as to whether ErbB4 is an oncogene or a tumor suppressor. 
While in some tissues ErbB4 promotes apoptosis, in others (including the colonic 
epithelium in this study) ErbB4 promotes survival. There have been several 
cancer treatments targeting ErbBs that have proven effective; for instance, the 
ErbB2 inhibitor herceptin has shown efficacy in treating breast cancer patients. 
Determining the role that each ErbB4 isoform plays in oncogenesis will be 
important for future therapeutics, not only for ErbB4 targeting drugs, but for drugs 
that target other ErbBs as well. Since members of this RTK family can 
heterodimerize to promote different biological outcomes, the signaling patterns of 
each ErbB4 isoform could affect how drugs targeting EGFR or ErbB2 function as 
well. Analyzing the apoptotic potential of individual ErbB4 isoform on a 
background devoid of other isoforms could shed light onto the specific signaling 
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cascades that each isoform initiates. Once ErbB4ʼs position as an oncogene or 
tumor suppressor has been fully characterized in different tissues, it will be 
possible to determine whether ErbB4 activation could possibly aid in the 
restitution of   cytokine-damaged intestinal epithelium in patients with IBD.  
 
 
  101 
REFERENCES 
 
 
Bersell, K., Arab, S., Haring, B., and Kuhn, B. (2009). Neuregulin1/ErbB4 
signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 
257-270. 
Bischoff, S.C., Lorentz, A., Schwengberg, S., Weier, G., Raab, R., and 
Manns, M.P. (1999). Mast cells are an important cellular source of tumour 
necrosis factor alpha in human intestinal tissue. Gut 44, 643-652. 
Black, R.A. (2004). TIMP3 checks inflammation. Nat Genet 36, 934-935. 
Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, J.L., 
Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., Srinivasan, S., et al. 
(1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-
alpha from cells. Nature 385, 729-733. 
Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., and 
Montori, V. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk 
of serious infections and malignancies: systematic review and meta-analysis of 
rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285. 
Bouyain, S., Longo, P.A., Li, S., Ferguson, K.M., and Leahy, D.J. (2005). 
The extracellular region of ErbB4 adopts a tethered conformation in the absence 
of ligand. Proc Natl Acad Sci U S A 102, 15024-15029. 
Bruewer, M., Luegering, A., Kucharzik, T., Parkos, C.A., Madara, J.L., 
Hopkins, A.M., and Nusrat, A. (2003). Proinflammatory cytokines disrupt 
epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171, 
6164-6172. 
Brynskov, J., Foegh, P., Pedersen, G., Ellervik, C., Kirkegaard, T., 
Bingham, A., and Saermark, T. (2002). Tumour necrosis factor alpha converting 
enzyme (TACE) activity in the colonic mucosa of patients with inflammatory 
bowel disease. Gut 51, 37-43. 
Burgess, A.W., Cho, H.S., Eigenbrot, C., Ferguson, K.M., Garrett, T.P., 
Leahy, D.J., Lemmon, M.A., Sliwkowski, M.X., Ward, C.W., and Yokoyama, S. 
(2003). An open-and-shut case? Recent insights into the activation of EGF/ErbB 
receptors. Mol Cell 12, 541-552. 
Carpenter, G., King, L., Jr., and Cohen, S. (1978). Epidermal growth factor 
stimulates phosphorylation in membrane preparations in vitro. Nature 276, 409-
410. 
  102 
Carpenter, G., Lembach, K.J., Morrison, M.M., and Cohen, S. (1975). 
Characterization of the binding of 125-I-labeled epidermal growth factor to human 
fibroblasts. J Biol Chem 250, 4297-4304. 
Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., and 
Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis 
of tumors. Proc Natl Acad Sci U S A 72, 3666-3670. 
Chalaris, A., Adam, N., Sina, C., Rosenstiel, P., Lehmann-Koch, J., 
Schirmacher, P., Hartmann, D., Cichy, J., Gavrilova, O., Schreiber, S., et al. 
(2010). Critical role of the disintegrin metalloprotease ADAM17 for intestinal 
inflammation and regeneration in mice. J Exp Med 207, 1617-1624. 
Cheng, H. (1974a). Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine. II. Mucous cells. Am J Anat 141, 
481-501. 
Cheng, H. (1974b). Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine. IV. Paneth cells. Am J Anat 141, 
521-535. 
Cheng, H., and Leblond, C.P. (1974a). Origin, differentiation and renewal 
of the four main epithelial cell types in the mouse small intestine. I. Columnar cell. 
Am J Anat 141, 461-479. 
Cheng, H., and Leblond, C.P. (1974b). Origin, differentiation and renewal 
of the four main epithelial cell types in the mouse small intestine. III. Entero-
endocrine cells. Am J Anat 141, 503-519. 
Clayton, A.H., Walker, F., Orchard, S.G., Henderson, C., Fuchs, D., 
Rothacker, J., Nice, E.C., and Burgess, A.W. (2005). Ligand-induced dimer-
tetramer transition during the activation of the cell surface epidermal growth 
factor receptor-A multidimensional microscopy analysis. J Biol Chem 280, 30392-
30399. 
Cohen, S. (1962). Isolation of a mouse submaxillary gland protein 
accelerating incisor eruption and eyelid opening in the new-born animal. J Biol 
Chem 237, 1555-1562. 
Cohen, S. (1965). The stimulation of epidermal proliferation by a specific 
protein (EGF). Dev Biol 12, 394-407. 
Colon, A.L., Menchen, L.A., Hurtado, O., De Cristobal, J., Lizasoain, I., 
Leza, J.C., Lorenzo, P., and Moro, M.A. (2001). Implication of TNF-alpha 
convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and 
inflammation in an experimental model of colitis. Cytokine 16, 220-226. 
  103 
Cooper, J.A., Bowen-Pope, D.F., Raines, E., Ross, R., and Hunter, T. 
(1982). Similar effects of platelet-derived growth factor and epidermal growth 
factor on the phosphorylation of tyrosine in cellular proteins. Cell 31, 263-273. 
Corredor, J., Yan, F., Shen, C.C., Tong, W., John, S.K., Wilson, G., 
Whitehead, R., and Polk, D.B. (2003). Tumor necrosis factor regulates intestinal 
epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell 
Physiol 284, C953-961. 
Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix 
metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 
2387-2392. 
Crohn, B.B., Ginzburg, L., and Oppenheimer, G.D. (1984). Landmark 
article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. 
Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA 251, 73-79. 
Danielsen, A.J., and Maihle, N.J. (2002). The EGF/ErbB receptor family 
and apoptosis. Growth Factors 20, 1-15. 
Daub, H., Wallasch, C., Lankenau, A., Herrlich, A., and Ullrich, A. (1997). 
Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16, 
7032-7044. 
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., 
Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005). Somatic mutations of 
the protein kinase gene family in human lung cancer. Cancer Res 65, 7591-7595. 
Dehal, P., and Boore, J.L. (2005). Two rounds of whole genome 
duplication in the ancestral vertebrate. PLoS Biol 3, e314. 
Diaz-Rodriguez, E., Montero, J.C., Esparis-Ogando, A., Yuste, L., and 
Pandiella, A. (2002). Extracellular signal-regulated kinase phosphorylates tumor 
necrosis factor alpha-converting enzyme at threonine 735: a potential role in 
regulated shedding. Mol Biol Cell 13, 2031-2044. 
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., 
Ullrich, A., Schlessinger, J., and Waterfield, M.D. (1984). Close similarity of 
epidermal growth factor receptor and v-erb-B oncogene protein sequences. 
Nature 307, 521-527. 
Eaden, J.A., Abrams, K.R., and Mayberry, J.F. (2001). The risk of 
colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535. 
  104 
Eckhart, W., Hutchinson, M.A., and Hunter, T. (1979). An activity 
phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 18, 925-
933. 
Edelblum, K.L., Yan, F., Yamaoka, T., and Polk, D.B. (2006). Regulation 
of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm 
Bowel Dis 12, 413-424. 
Edwards, D.R., Handsley, M.M., and Pennington, C.J. (2008). The ADAM 
metalloproteinases. Mol Aspects Med 29, 258-289. 
Ek, B., Westermark, B., Wasteson, A., and Heldin, C.H. (1982). 
Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. 
Nature 295, 419-420. 
Elenius, K., Choi, C.J., Paul, S., Santiestevan, E., Nishi, E., and 
Klagsbrun, M. (1999). Characterization of a naturally occurring ErbB4 isoform 
that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18, 2607-
2615. 
Elenius, K., Corfas, G., Paul, S., Choi, C.J., Rio, C., Plowman, G.D., and 
Klagsbrun, M. (1997). A novel juxtamembrane domain isoform of HER4/ErbB4. 
Isoform-specific tissue distribution and differential processing in response to 
phorbol ester. J Biol Chem 272, 26761-26768. 
Erlich, S., Goldshmit, Y., Lupowitz, Z., and Pinkas-Kramarski, R. (2001). 
ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience 107, 353-362. 
Eto, K., Hommyo, A., Yonemitsu, R., and Abe, S. (2010 
). ErbB4 signals Neuregulin1-stimulated cell proliferation and c-fos gene 
expression through phosphorylation of serum response factor by mitogen-
activated protein kinase cascade. Mol Cell Biochem 339, 119-125. 
Falls, D.L. (2003). Neuregulins: functions, forms, and signaling strategies. 
Exp Cell Res 284, 14-30. 
Fan, H., Turck, C.W., and Derynck, R. (2003). Characterization of growth 
factor-induced serine phosphorylation of tumor necrosis factor-alpha converting 
enzyme and of an alternatively translated polypeptide. J Biol Chem 278, 18617-
18627. 
Fielding, J.F. (1988). Crohn's disease and Dalziel's syndrome. A history. J 
Clin Gastroenterol 10, 279-285. 
Freour, T., Jarry, A., Bach-Ngohou, K., Dejoie, T., Bou-Hanna, C., Denis, 
M.G., Mosnier, J.F., Laboisse, C.L., and Masson, D. (2009). TACE inhibition 
  105 
amplifies TNF-alpha-mediated colonic epithelial barrier disruption. Int J Mol Med 
23, 41-48. 
Frey, M.R., Edelblum, K.L., Mullane, M.T., Liang, D., and Polk, D.B. 
(2009). The ErbB4 growth factor receptor is required for colon epithelial cell 
survival in the presence of TNF. Gastroenterology 136, 217-226. 
Frey, M.R., Hilliard, V.C., Mullane, M.T., and Polk, D.B. (2010). ErbB4 
promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells. 
Lab Invest. 
Fuss, I.J., Becker, C., Yang, Z., Groden, C., Hornung, R.L., Heller, F., 
Neurath, M.F., Strober, W., and Mannon, P.J. (2006). Both IL-12p70 and IL-23 
are synthesized during active Crohn's disease and are down-regulated by 
treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12, 9-15. 
Fuss, I.J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, 
S., Yang, Z., Exley, M., Kitani, A., Blumberg, R.S., et al. (2004). Nonclassical 
CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 
response in ulcerative colitis. J Clin Invest 113, 1490-1497. 
Gadella, T.W., Jr., and Jovin, T.M. (1995). Oligomerization of epidermal 
growth factor receptors on A431 cells studied by time-resolved fluorescence 
imaging microscopy. A stereochemical model for tyrosine kinase receptor 
activation. J Cell Biol 129, 1543-1558. 
Gambarotta, G., Garzotto, D., Destro, E., Mautino, B., Giampietro, C., 
Cutrupi, S., Dati, C., Cattaneo, E., Fasolo, A., and Perroteau, I. (2004). ErbB4 
expression in neural progenitor cells (ST14A) is necessary to mediate 
neuregulin-1beta1-induced migration. J Biol Chem 279, 48808-48816. 
Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., 
Lovrecz, G.O., Zhu, H.J., Walker, F., Frenkel, M.J., Hoyne, P.A., et al. (2002). 
Crystal structure of a truncated epidermal growth factor receptor extracellular 
domain bound to transforming growth factor alpha. Cell 110, 763-773. 
Garton, K.J., Gough, P.J., Philalay, J., Wille, P.T., Blobel, C.P., 
Whitehead, R.H., Dempsey, P.J., and Raines, E.W. (2003). Stimulated shedding 
of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis 
factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278, 37459-37464. 
Ghashghaei, H.T., Weber, J., Pevny, L., Schmid, R., Schwab, M.H., Lloyd, 
K.C., Eisenstat, D.D., Lai, C., and Anton, E.S. (2006). The role of neuregulin-
ErbB4 interactions on the proliferation and organization of cells in the 
subventricular zone. Proc Natl Acad Sci U S A 103, 1930-1935. 
  106 
Ghayad, S.E., Vendrell, J.A., Larbi, S.B., Dumontet, C., Bieche, I., and 
Cohen, P.A. (2009). Endocrine resistance associated with activated ErbB system 
in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling 
pathways. Int J Cancer 126, 545-562. 
Gooz, M. (2010). ADAM-17: the enzyme that does it all. Crit Rev Biochem 
Mol Biol 45, 146-169. 
Graus-Porta, D., Beerli, R.R., Daly, J.M., and Hynes, N.E. (1997). ErbB-2, 
the preferred heterodimerization partner of all ErbB receptors, is a mediator of 
lateral signaling. EMBO J 16, 1647-1655. 
Grell, M., Wajant, H., Zimmermann, G., and Scheurich, P. (1998). The 
type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis 
factor. Proc Natl Acad Sci U S A 95, 570-575. 
Gschwind, A., Fischer, O.M., and Ullrich, A. (2004). The discovery of 
receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4, 361-
370. 
Gutierrez, C., and Schiff, R. (2011). HER2: biology, detection, and clinical 
implications. Arch Pathol Lab Med 135, 55-62. 
Hagiwara, C., Tanaka, M., and Kudo, H. (2002). Increase in colorectal 
epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring 
surgery. J Gastroenterol Hepatol 17, 758-764. 
Hahn, D., Pischitzis, A., Roesmann, S., Hansen, M.K., Leuenberger, B., 
Luginbuehl, U., and Sterchi, E.E. (2003). Phorbol 12-myristate 13-acetate-
induced ectodomain shedding and phosphorylation of the human meprinbeta 
metalloprotease. J Biol Chem 278, 42829-42839. 
Hall, P.A., Coates, P.J., Ansari, B., and Hopwood, D. (1994). Regulation of 
cell number in the mammalian gastrointestinal tract: the importance of apoptosis. 
J Cell Sci 107 ( Pt 12), 3569-3577. 
Hampe, J., Schreiber, S., Shaw, S.H., Lau, K.F., Bridger, S., Macpherson, 
A.J., Cardon, L.R., Sakul, H., Harris, T.J., Buckler, A., et al. (1999). A 
genomewide analysis provides evidence for novel linkages in inflammatory bowel 
disease in a large European cohort. Am J Hum Genet 64, 808-816. 
Hanks, S.K., Quinn, A.M., and Hunter, T. (1988). The protein kinase 
family: conserved features and deduced phylogeny of the catalytic domains. 
Science 241, 42-52. 
  107 
Harris, J., and Keane, J. (2010). How tumour necrosis factor blockers 
interfere with tuberculosis immunity. Clin Exp Immunol 161, 1-9. 
Harris, R.C., Chung, E., and Coffey, R.J. (2003). EGF receptor ligands. 
Exp Cell Res 284, 2-13. 
Helson, L., Green, S., Carswell, E., and Old, L.J. (1975). Effect of tumour 
necrosis factor on cultured human melanoma cells. Nature 258, 731-732. 
Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. (2005). 
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug 
Discov 4, 988-1004. 
Heresbach, D., Gulwani-Akolkar, B., Lesser, M., Akolkar, P.N., Lin, X.Y., 
Heresbach-Le Berre, N., Bretagne, J.F., Katz, S., and Silver, J. (1998). 
Anticipation in Crohn's disease may be influenced by gender and ethnicity of the 
transmitting parent. Am J Gastroenterol 93, 2368-2372. 
Higashiyama, S., and Nanba, D. (2005). ADAM-mediated ectodomain 
shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 1751, 110-
117. 
Himanen, J.P., and Nikolov, D.B. (2003). Eph signaling: a structural view. 
Trends Neurosci 26, 46-51. 
Hinkle, C.L., Sunnarborg, S.W., Loiselle, D., Parker, C.E., Stevenson, M., 
Russell, W.E., and Lee, D.C. (2004). Selective roles for tumor necrosis factor 
alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor 
receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J 
Biol Chem 279, 24179-24188. 
Honegger, A.M., Kris, R.M., Ullrich, A., and Schlessinger, J. (1989). 
Evidence that autophosphorylation of solubilized receptors for epidermal growth 
factor is mediated by intermolecular cross-phosphorylation. Proc Natl Acad Sci U 
S A 86, 925-929. 
Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J.P., 
Belaiche, J., Almer, S., Tysk, C., O'Morain, C.A., Gassull, M., et al. (2001). 
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's 
disease. Nature 411, 599-603. 
Hunter, T., and Cooper, J.A. (1981). Epidermal growth factor induces rapid 
tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 24, 741-
752. 
  108 
Hunter, T., and Sefton, B.M. (1980). Transforming gene product of Rous 
sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A 77, 1311-1315. 
Huovila, A.P., Turner, A.J., Pelto-Huikko, M., Karkkainen, I., and Ortiz, 
R.M. (2005). Shedding light on ADAM metalloproteinases. Trends Biochem Sci 
30, 413-422. 
Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein 
kinases. Cell 109, 275-282. 
Irby, R.B., and Yeatman, T.J. (2000). Role of Src expression and 
activation in human cancer. Oncogene 19, 5636-5642. 
Iwamoto, M., Koji, T., Makiyama, K., Kobayashi, N., and Nakane, P.K. 
(1996). Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 180, 152-
159. 
Jeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, 
J., and Pavletich, N.P. (1995). Mechanism of CDK activation revealed by the 
structure of a cyclinA-CDK2 complex. Nature 376, 313-320. 
Junttila, T.T., Sundvall, M., Lundin, M., Lundin, J., Tanner, M., Harkonen, 
P., Joensuu, H., Isola, J., and Elenius, K. (2005). Cleavable ErbB4 isoform in 
estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65, 1384-
1393. 
Kainulainen, V., Sundvall, M., Maatta, J.A., Santiestevan, E., Klagsbrun, 
M., and Elenius, K. (2000). A natural ErbB4 isoform that does not activate 
phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J 
Biol Chem 275, 8641-8649. 
Kaiser, G.C., and Polk, D.B. (1997). Tumor necrosis factor alpha regulates 
proliferation in a mouse intestinal cell line. Gastroenterology 112, 1231-1240. 
Kang, H.G., Jenabi, J.M., Zhang, J., Keshelava, N., Shimada, H., May, 
W.A., Ng, T., Reynolds, C.P., Triche, T.J., and Sorensen, P.H. (2007). E-
cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis 
through activation of the ErbB4 tyrosine kinase. Cancer Res 67, 3094-3105. 
Kasuga, M., Zick, Y., Blithe, D.L., Crettaz, M., and Kahn, C.R. (1982). 
Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free 
system. Nature 298, 667-669. 
Kataoka, H., Joh, T., Kasugai, K., Okayama, N., Moriyama, A., Asai, K., 
and Kato, T. (1998). Expression of mRNA for heregulin and its receptor, ErbB-3 
and ErbB-4, in human upper gastrointestinal mucosa. Life Sci 63, 553-564. 
  109 
Kaushansky, A., Gordus, A., Budnik, B.A., Lane, W.S., Rush, J., and 
MacBeath, G. (2008). System-wide investigation of ErbB4 reveals 19 sites of Tyr 
phosphorylation that are unusually selective in their recruitment properties. Chem 
Biol 15, 808-817. 
Killock, D.J., and Ivetic, A. (2010). The cytoplasmic domains of TNFalpha-
converting enzyme (TACE/ADAM17) and L-selectin are regulated differently by 
p38 MAPK and PKC to promote ectodomain shedding. Biochem J 428, 293-304. 
Knighton, D.R., Zheng, J.H., Ten Eyck, L.F., Ashford, V.A., Xuong, N.H., 
Taylor, S.S., and Sowadski, J.M. (1991). Crystal structure of the catalytic subunit 
of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 
407-414. 
Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F., and Kollias, 
G. (1999). Impaired on/off regulation of TNF biosynthesis in mice lacking TNF 
AU-rich elements: implications for joint and gut-associated immunopathologies. 
Immunity 10, 387-398. 
Kritzik, M.R., Krahl, T., Good, A., Gu, D., Lai, C., Fox, H., and Sarvetnick, 
N. (2000). Expression of ErbB receptors during pancreatic islet development and 
regrowth. J Endocrinol 165, 67-77. 
Kveiborg, M., Frohlich, C., Albrechtsen, R., Tischler, V., Dietrich, N., 
Holck, P., Kronqvist, P., Rank, F., Mercurio, A.M., and Wewer, U.M. (2005). A 
role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer 
Res 65, 4754-4761. 
Lee, D., Yu, M., Lee, E., Kim, H., Yang, Y., Kim, K., Pannicia, C., Kurie, 
J.M., and Threadgill, D.W. (2009). Tumor-specific apoptosis caused by deletion 
of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 119, 
2702-2713. 
Lee, J.C., Wang, S.T., Chow, N.H., and Yang, H.B. (2002). Investigation of 
the prognostic value of coexpressed erbB family members for the survival of 
colorectal cancer patients after curative surgery. Eur J Cancer 38, 1065-1071. 
Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor 
tyrosine kinases. Cell 141, 1117-1134. 
Leung, S.P., Griffith, O.L., Masoudi, H., Gown, A., Jones, S., Phang, T., 
and Wiseman, S.M. (2008). Clinical utility of type 1 growth factor receptor 
expression in colon cancer. Am J Surg 195, 604-610. 
  110 
Lim, H., Das, S.K., and Dey, S.K. (1998). erbB genes in the mouse uterus: 
cell-specific signaling by epidermal growth factor (EGF) family of growth factors 
during implantation. Dev Biol 204, 97-110. 
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova-
Scholz, M., Gromnica-Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005). 
Infections in patients with rheumatoid arthritis treated with biologic agents. 
Arthritis Rheum 52, 3403-3412. 
Liu, H., Chen, X., Focia, P.J., and He, X. (2007a). Structural basis for stem 
cell factor-KIT signaling and activation of class III receptor tyrosine kinases. 
EMBO J 26, 891-901. 
Liu, W., Zscheppang, K., Murray, S., Nielsen, H.C., and Dammann, C.E. 
(2007b). The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II 
cells. Biochim Biophys Acta 1772, 737-747. 
Loftus, E.V., Jr. (2004). Clinical epidemiology of inflammatory bowel 
disease: Incidence, prevalence, and environmental influences. Gastroenterology 
126, 1504-1517. 
Long, W., Wagner, K.U., Lloyd, K.C., Binart, N., Shillingford, J.M., 
Hennighausen, L., and Jones, F.E. (2003). Impaired differentiation and lactational 
failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate 
mediator of STAT5. Development 130, 5257-5268. 
Luzi, L., Confalonieri, S., Di Fiore, P.P., and Pelicci, P.G. (2000). Evolution 
of Shc functions from nematode to human. Curr Opin Genet Dev 10, 668-674. 
Maatta, J.A., Sundvall, M., Junttila, T.T., Peri, L., Laine, V.J., Isola, J., 
Egeblad, M., and Elenius, K. (2006). Proteolytic cleavage and phosphorylation of 
a tumor-associated ErbB4 isoform promote ligand-independent survival and 
cancer cell growth. Mol Biol Cell 17, 67-79. 
Manicone, A.M., and McGuire, J.K. (2008). Matrix metalloproteinases as 
modulators of inflammation. Semin Cell Dev Biol 19, 34-41. 
Manning, G., and Scheeff, E. (2010). How the vertebrates were made: 
selective pruning of a double-duplicated genome. BMC Biol 8, 144. 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. 
(2002). The protein kinase complement of the human genome. Science 298, 
1912-1934. 
Maretzky, T., Zhou, W., Huang, X.Y., and Blobel, C.P. (2011). A 
transforming Src mutant increases the bioavailability of EGFR ligands via 
  111 
stimulation of the cell-surface metalloproteinase ADAM17. Oncogene 30, 611-
618. 
Mazzocca, A., Coppari, R., De Franco, R., Cho, J.Y., Libermann, T.A., 
Pinzani, M., and Toker, A. (2005). A secreted form of ADAM9 promotes 
carcinoma invasion through tumor-stromal interactions. Cancer Res 65, 4728-
4738. 
McLysaght, A., Hokamp, K., and Wolfe, K.H. (2002). Extensive genomic 
duplication during early chordate evolution. Nat Genet 31, 200-204. 
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., 
Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009). Gefitinib or 
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-
957. 
Montero, J.C., Yuste, L., Diaz-Rodriguez, E., Esparis-Ogando, A., and 
Pandiella, A. (2000). Differential shedding of transmembrane neuregulin isoforms 
by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci 16, 
631-648. 
Moss, M.L., Jin, S.L., Milla, M.E., Bickett, D.M., Burkhart, W., Carter, H.L., 
Chen, W.J., Clay, W.C., Didsbury, J.R., Hassler, D., et al. (1997). Cloning of a 
disintegrin metalloproteinase that processes precursor tumour-necrosis factor-
alpha. Nature 385, 733-736. 
Najy, A.J., Day, K.C., and Day, M.L. (2008). ADAM15 supports prostate 
cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer 
Res 68, 1092-1099. 
Naresh, A., Long, W., Vidal, G.A., Wimley, W.C., Marrero, L., Sartor, C.I., 
Tovey, S., Cooke, T.G., Bartlett, J.M., and Jones, F.E. (2006). The ERBB4/HER4 
intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast 
cancer cells. Cancer Res 66, 6412-6420. 
Newton, R.C., Solomon, K.A., Covington, M.B., Decicco, C.P., Haley, P.J., 
Friedman, S.M., and Vaddi, K. (2001). Biology of TACE inhibition. Ann Rheum 
Dis 60 Suppl 3, iii25-32. 
Niv, Y., Abuksis, G., and Fraser, G.M. (2000). Epidemiology of ulcerative 
colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 95, 
693-698. 
Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F., Ramos, R., 
Britton, H., Moran, T., Karaliuskas, R., Duerr, R.H., et al. (2001a). A frameshift 
  112 
mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 
603-606. 
Ogura, Y., Inohara, N., Benito, A., Chen, F.F., Yamaoka, S., and Nunez, 
G. (2001b). Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes 
and activates NF-kappaB. J Biol Chem 276, 4812-4818. 
Orholm, M., Binder, V., Sorensen, T.I., Rasmussen, L.P., and Kyvik, K.O. 
(2000). Concordance of inflammatory bowel disease among Danish twins. 
Results of a nationwide study. Scand J Gastroenterol 35, 1075-1081. 
Parsons, D.W., Wang, T.L., Samuels, Y., Bardelli, A., Cummins, J.M., 
DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J.K., et al. (2005). 
Colorectal cancer: mutations in a signalling pathway. Nature 436, 792. 
Peduto, L., Reuter, V.E., Sehara-Fujisawa, A., Shaffer, D.R., Scher, H.I., 
and Blobel, C.P. (2006). ADAM12 is highly expressed in carcinoma-associated 
stroma and is required for mouse prostate tumor progression. Oncogene 25, 
5462-5466. 
Peiretti, F., Canault, M., Deprez-Beauclair, P., Berthet, V., Bonardo, B., 
Juhan-Vague, I., and Nalbone, G. (2003). Intracellular maturation and transport 
of tumor necrosis factor alpha converting enzyme. Exp Cell Res 285, 278-285. 
Peltekova, V.D., Wintle, R.F., Rubin, L.A., Amos, C.I., Huang, Q., Gu, X., 
Newman, B., Van Oene, M., Cescon, D., Greenberg, G., et al. (2004). Functional 
variants of OCTN cation transporter genes are associated with Crohn disease. 
Nat Genet 36, 471-475. 
Plowman, G.D., Culouscou, J.M., Whitney, G.S., Green, J.M., Carlton, 
G.W., Foy, L., Neubauer, M.G., and Shoyab, M. (1993). Ligand-specific activation 
of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor 
family. Proc Natl Acad Sci U S A 90, 1746-1750. 
Ponz-Sarvise, M., Rodriguez, J., Viudez, A., Chopitea, A., Calvo, A., 
Garcia-Foncillas, J., and Gil-Bazo, I. (2007). Epidermal growth factor receptor 
inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 13, 
5877-5887. 
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., 
and Ullrich, A. (1999). EGF receptor transactivation by G-protein-coupled 
receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-
888. 
Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, 
J.R., Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y. (2009). Analysis 
  113 
of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat 
Genet 41, 1127-1132. 
Qiu, C., Tarrant, M.K., Choi, S.H., Sathyamurthy, A., Bose, R., Banjade, 
S., Pal, A., Bornmann, W.G., Lemmon, M.A., Cole, P.A., et al. (2008). 
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16, 
460-467. 
Riedel, H., Dull, T.J., Schlessinger, J., and Ullrich, A. (1986). A chimaeric 
receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth 
factor receptor. Nature 324, 68-70. 
Rose-John, S., Chalaris, A., and Adam, N. (2009). Intestinal Inflammation 
is coordinated by the metalloprotease ADAM17. Cytokine 48, 51-52. 
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., 
Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009). Screening 
for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 
958-967. 
Rudloff, U., and Samuels, Y. (2010). A growing family: Adding mutated 
Erbb4 as a novel cancer target. Cell Cycle 9. 
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, 
M., Williams, C., Price, A., Talbot, I., and Forbes, A. (2004). Severity of 
inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. 
Gastroenterology 126, 451-459. 
Sanderson, M.P., Dempsey, P.J., and Dunbar, A.J. (2006). Control of 
ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-
like factors. Growth Factors 24, 121-136. 
Satsangi, J., Grootscholten, C., Holt, H., and Jewell, D.P. (1996). Clinical 
patterns of familial inflammatory bowel disease. Gut 38, 738-741. 
Schafer, B., Marg, B., Gschwind, A., and Ullrich, A. (2004). Distinct ADAM 
metalloproteinases regulate G protein-coupled receptor-induced cell proliferation 
and survival. J Biol Chem 279, 47929-47938. 
Schlessinger, J., Plotnikov, A.N., Ibrahimi, O.A., Eliseenkova, A.V., Yeh, 
B.K., Yayon, A., Linhardt, R.J., and Mohammadi, M. (2000). Crystal structure of a 
ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR 
binding and dimerization. Mol Cell 6, 743-750. 
  114 
Schlondorff, J., Becherer, J.D., and Blobel, C.P. (2000). Intracellular 
maturation and localization of the tumour necrosis factor alpha convertase 
(TACE). Biochem J 347 Pt 1, 131-138. 
Schlondorff, J., and Blobel, C.P. (1999). Metalloprotease-disintegrins: 
modular proteins capable of promoting cell-cell interactions and triggering signals 
by protein-ectodomain shedding. J Cell Sci 112 ( Pt 21), 3603-3617. 
Schmidt, G.H., Wilkinson, M.M., and Ponder, B.A. (1985). Cell migration 
pathway in the intestinal epithelium: an in situ marker system using mouse 
aggregation chimeras. Cell 40, 425-429. 
Schulze, W.X., Deng, L., and Mann, M. (2005). Phosphotyrosine 
interactome of the ErbB-receptor kinase family. Mol Syst Biol 1, 2005 0008. 
Schulzke, J.D., Bojarski, C., Zeissig, S., Heller, F., Gitter, A.H., and 
Fromm, M. (2006). Disrupted barrier function through epithelial cell apoptosis. 
Ann N Y Acad Sci 1072, 288-299. 
Shirakabe, K., Wakatsuki, S., Kurisaki, T., and Fujisawa-Sehara, A. 
(2001). Roles of Meltrin beta /ADAM19 in the processing of neuregulin. J Biol 
Chem 276, 9352-9358. 
Smookler, D.S., Mohammed, F.F., Kassiri, Z., Duncan, G.S., Mak, T.W., 
and Khokha, R. (2006). Tissue inhibitor of metalloproteinase 3 regulates TNF-
dependent systemic inflammation. J Immunol 176, 721-725. 
Soond, S.M., Everson, B., Riches, D.W., and Murphy, G. (2005). ERK-
mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its 
potential role in TACE protein trafficking. J Cell Sci 118, 2371-2380. 
Soung, Y.H., Lee, J.W., Kim, S.Y., Wang, Y.P., Jo, K.H., Moon, S.W., 
Park, W.S., Nam, S.W., Lee, J.Y., Yoo, N.J., et al. (2006). Somatic mutations of 
the ERBB4 kinase domain in human cancers. Int J Cancer 118, 1426-1429. 
Spring, J. (2002). Genome duplication strikes back. Nat Genet 31, 128-
129. 
Stoll, M., Corneliussen, B., Costello, C.M., Waetzig, G.H., Mellgard, B., 
Koch, W.A., Rosenstiel, P., Albrecht, M., Croucher, P.J., Seegert, D., et al. 
(2004). Genetic variation in DLG5 is associated with inflammatory bowel disease. 
Nat Genet 36, 476-480. 
Strober, W., Fuss, I., and Mannon, P. (2007). The fundamental basis of 
inflammatory bowel disease. J Clin Invest 117, 514-521. 
  115 
Tanabe, T., Chamaillard, M., Ogura, Y., Zhu, L., Qiu, S., Masumoto, J., 
Ghosh, P., Moran, A., Predergast, M.M., Tromp, G., et al. (2004). Regulatory 
regions and critical residues of NOD2 involved in muramyl dipeptide recognition. 
EMBO J 23, 1587-1597. 
Tellier, E., Canault, M., Rebsomen, L., Bonardo, B., Juhan-Vague, I., 
Nalbone, G., and Peiretti, F. (2006). The shedding activity of ADAM17 is 
sequestered in lipid rafts. Exp Cell Res 312, 3969-3980. 
Terzic, J., Grivennikov, S., Karin, E., and Karin, M. (2010). Inflammation 
and colon cancer. Gastroenterology 138, 2101-2114 e2105. 
Thompson, N.P., Driscoll, R., Pounder, R.E., and Wakefield, A.J. (1996). 
Genetics versus environment in inflammatory bowel disease: results of a British 
twin study. BMJ 312, 95-96. 
Tidcombe, H., Jackson-Fisher, A., Mathers, K., Stern, D.F., Gassmann, 
M., and Golding, J.P. (2003). Neural and mammary gland defects in ErbB4 
knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci U 
S A 100, 8281-8286. 
Till, J.H., Becerra, M., Watty, A., Lu, Y., Ma, Y., Neubert, T.A., Burden, 
S.J., and Hubbard, S.R. (2002). Crystal structure of the MuSK tyrosine kinase: 
insights into receptor autoregulation. Structure 10, 1187-1196. 
Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., and Tak, P.P. (2008). 
Tumor necrosis factor antagonist mechanisms of action: a comprehensive 
review. Pharmacol Ther 117, 244-279. 
Tvorogov, D., Sundvall, M., Kurppa, K., Hollmen, M., Repo, S., Johnson, 
M.S., and Elenius, K. (2009). Somatic mutations of ErbB4: selective loss-of-
function phenotype affecting signal transduction pathways in cancer. J Biol Chem 
284, 5582-5591. 
Tysk, C., Lindberg, E., Jarnerot, G., and Floderus-Myrhed, B. (1988). 
Ulcerative colitis and Crohn's disease in an unselected population of monozygotic 
and dizygotic twins. A study of heritability and the influence of smoking. Gut 29, 
990-996. 
Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., 
Lee, J., Yarden, Y., Libermann, T.A., Schlessinger, J., et al. (1984). Human 
epidermal growth factor receptor cDNA sequence and aberrant expression of the 
amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425. 
Ullrich, A., and Schlessinger, J. (1990). Signal transduction by receptors 
with tyrosine kinase activity. Cell 61, 203-212. 
  116 
Ushiro, H., and Cohen, S. (1980). Identification of phosphotyrosine as a 
product of epidermal growth factor-activated protein kinase in A-431 cell 
membranes. J Biol Chem 255, 8363-8365. 
Van Antwerp, D.J., Martin, S.J., Verma, I.M., and Green, D.R. (1998). 
Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol 8, 107-111. 
van der Horst, E.H., Degenhardt, Y.Y., Strelow, A., Slavin, A., Chinn, L., 
Orf, J., Rong, M., Li, S., See, L.H., Nguyen, K.Q., et al. (2005). Metastatic 
properties and genomic amplification of the tyrosine kinase gene ACK1. Proc 
Natl Acad Sci U S A 102, 15901-15906. 
Van Deventer, S.J. (1997). Tumour necrosis factor and Crohn's disease. 
Gut 40, 443-448. 
Vidal, G.A., Clark, D.E., Marrero, L., and Jones, F.E. (2007). A 
constitutively active ERBB4/HER4 allele with enhanced transcriptional 
coactivation and cell-killing activities. Oncogene 26, 462-466. 
Wang, X., He, K., Gerhart, M., Huang, Y., Jiang, J., Paxton, R.J., Yang, S., 
Lu, C., Menon, R.K., Black, R.A., et al. (2002). Metalloprotease-mediated GH 
receptor proteolysis and GHBP shedding. Determination of extracellular domain 
stem region cleavage site. J Biol Chem 277, 50510-50519. 
Wang, X., Oka, T., Chow, F.L., Cooper, S.B., Odenbach, J., Lopaschuk, 
G.D., Kassiri, Z., and Fernandez-Patron, C. (2009). Tumor necrosis factor-alpha-
converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and 
fibrosis. Hypertension 54, 575-582. 
Whitehead, R.H., VanEeden, P.E., Noble, M.D., Ataliotis, P., and Jat, P.S. 
(1993). Establishment of conditionally immortalized epithelial cell lines from both 
colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad 
Sci U S A 90, 587-591. 
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A., and 
de Vos, A.M. (1997). Crystal structure at 1.7 A resolution of VEGF in complex 
with domain 2 of the Flt-1 receptor. Cell 91, 695-704. 
Wiesmann, C., Ultsch, M.H., Bass, S.H., and de Vos, A.M. (1999). Crystal 
structure of nerve growth factor in complex with the ligand-binding domain of the 
TrkA receptor. Nature 401, 184-188. 
Wilks, S. (1859). Morbid appearances in the intestine of Miss Bankes. 
London Medical Times and Gazette 2, 264. 
  117 
Williams, E.E., Trout, L.J., Gallo, R.M., Pitfield, S.E., Bryant, I., Penington, 
D.J., and Riese, D.J., 2nd (2003). A constitutively active ErbB4 mutant inhibits 
drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor 
cell lines. Cancer Lett 192, 67-74. 
Winter, S.E., Keestra, A.M., Tsolis, R.M., and Baumler, A.J. (2010) The 
blessings and curses of intestinal inflammation. Cell Host Microbe 8, 36-43. 
Wu, W.K., Tse, T.T., Sung, J.J., Li, Z.J., Yu, L., and Cho, C.H. (2009). 
Expression of ErbB receptors and their cognate ligands in gastric and colon 
cancer cell lines. Anticancer Res 29, 229-234. 
Xu, P., and Derynck, R. (2010). Direct activation of TACE-mediated 
ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell 
proliferation. Mol Cell 37, 551-566. 
Yamaoka, T., Yan, F., Cao, H., Hobbs, S.S., Dise, R.S., Tong, W., and 
Polk, D.B. (2008). Transactivation of EGF receptor and ErbB2 protects intestinal 
epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci U S A 105, 
11772-11777. 
Yan, F., Cao, H., Chaturvedi, R., Krishna, U., Hobbs, S.S., Dempsey, P.J., 
Peek, R.M., Jr., Cover, T.L., Washington, M.K., Wilson, K.T., et al. (2009). 
Epidermal growth factor receptor activation protects gastric epithelial cells from 
Helicobacter pylori-induced apoptosis. Gastroenterology 136, 1297-1307, e1291-
1293. 
Yotsumoto, F., Oki, E., Tokunaga, E., Maehara, Y., Kuroki, M., and 
Miyamoto, S. (2010) HB-EGF orchestrates the complex signals involved in triple-
negative and trastuzumab-resistant breast cancer. Int J Cancer 127, 2707-2717. 
Zeng, F., Xu, J., and Harris, R.C. (2009). Nedd4 mediates ErbB4 JM-
a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J 23, 1935-
1945. 
Zhang, Q., Thomas, S.M., Lui, V.W., Xi, S., Siegfried, J.M., Fan, H., 
Smithgall, T.E., Mills, G.B., and Grandis, J.R. (2006a). Phosphorylation of TNF-
alpha converting enzyme by gastrin-releasing peptide induces amphiregulin 
release and EGF receptor activation. Proc Natl Acad Sci U S A 103, 6901-6906. 
Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. (2006b). An 
allosteric mechanism for activation of the kinase domain of epidermal growth 
factor receptor. Cell 125, 1137-1149. 
 
 
 
